var docs;if (!docs) docs =[]; docs["53"]={"5300":"<p><b>Title</b> FLUoxetine / Propafenone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Propafenone may enhance the QTc-prolonging effect of FLUoxetine. FLUoxetine may increase the serum concentration of Propafenone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The concomitant use of fluoxetine with propafenone is expected to substantially increase the risk for serious toxicities, including the development of torsades de pointes or other significant ventricular tachyarrhythmias, and should be avoided. This risk may be further enhanced by fluoxetine mediated increases in propafenone exposure. Patients with other risk factors present (e.g., older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations), would be at an even higher risk for these potentially life-threatening effects.</p> \n<p><b>Discussion</b> Propafenone AUC was an average of 50% higher when propafenone (400 mg x1) was administered on day 10 of fluoxetine administration (20 mg/day) to 9 healthy Chinese volunteers.<sup>1</sup> Maximum serum concentrations (Cmax) of propafenone were also impacted, though in a stereoselective manner, with S-propafenone an average of 39% higher and R-propafenone an average of 71% higher. An in vitro study using human liver microsomes similarly concluded that both fluoxetine and its active metabolite norfluoxetine were both fairly potent inhibitors of propafenone 5-hydroxylation, which is the primary route of propafenone metabolism.<sup>2</sup> Neither fluoxetine or norfluoxetine were potent inhibitors of propafenone N-dealkylation, a secondary route of propafenone metabolism.<br><br>The mechanism for this possible interaction is likely fluoxetine- (and norfluoxetine-) mediated inhibition of propafenone 5-hydroxylation via CYP2D6. This is consistent with the known abilities of fluoxetine and norfluoxetine to potently inhibit CYP2D6 activity.<sup>3,4,5</sup> In addition to the potential for increased propafenone concentrations with this combination, both drugs have the capacity to prolong QTc interval, and their combination may consequently increase the risk of torsades de pointes or other significant ventricular tachyarrhythmias.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cai WM, Chen B, Zhou Y, et al, “Fluoxetine Impairs the CYP2D6-Mediated Metabolism of Propafenone Enantiomers in Healthy Chinese Volunteers,” <i>Clin Pharmacol Ther</i>, 1999, 66(5):516-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10579479\">[PubMed 10579479]</a></p>\n<p>2. Hemeryck A, De Vriendt C, Belpaire FM, “Effect of Selective Serotonin Reuptake Inhibitors on the Oxidative Metabolism of Propafenone: In Vitro Studies Using Human Liver Microsomes,” <i>J Clin Psychopharmacol</i>, 2000, 20(4):428-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10917404\">[PubMed 10917404]</a></p>\n<p>3. Belpaire FM, Wijnant P, Temmerman A, et al, “The Oxidative Metabolism of Metoprolol in Human Liver Microsomes: Inhibition by the Selective Serotonin Reuptake Inhibitors,” <i>Eur J Clin Pharmacol</i>, 1998, 54(3):261-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9681670\">[PubMed 9681670]</a></p>\n<p>4. Volotinen M, Korjamo T, Tolonen A, et al, “Effects of Selective Serotonin Reuptake Inhibitors on Timolol Metabolism in Human Liver Microsomes and Cryo-Preserved Hepatocytes,” <i>Basic Clin Pharmacol Toxicol</i>, 2009, Nov 11 [Epub ahead of print]. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19912165\">[PubMed 19912165]</a></p>\n<p>5. Hara Y, Nakajima M, Miyamoto KI, et al, “Inhibitory Effects of Psychotropic Drugs on Mexiletine Metabolism in Human Liver Microsomes: Prediction of In Vivo Drug Interactions,” <i>Xenobiotica</i>, 2005, 35(6):549-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16192107\">[PubMed 16192107]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5301":"<p><b>Title</b> Propafenone / PARoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PARoxetine may increase the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to propafenone closely when used together with paroxetine, particularly watching for signs/symptoms of propafenone toxicity (including monitoring ECG for QT prolongation or other signs of pro-arrhythmia).</p> \n<p><b>Discussion</b> An in vitro study using human liver microsomes concluded that paroxetine was a fairly potent inhibitor of propafenone 5-hydroxylation, which is the primary route of propafenone metabolism.<sup>1</sup> Paroxetine was not, however, a potent inhibitor of propafenone N-dealkylation, a secondary route of propafenone metabolism. Fluoxetine, another selective serotonin reuptake inhibitor that is a potent inhibitor of CYP2D6 (like paroxetine), was also shown to potently inhibit propafenone 5-hydroxylation but not its N-dealkylation.<br><br>Of note, propafenone AUC was an average of 50% higher when propafenone (400 mg x1) was administered on day 10 of fluoxetine administration (20 mg/day) to 9 healthy Chinese volunteers.<sup>2</sup> Maximum serum concentrations (Cmax) of propafenone were also impacted, though in a stereoselective manner, with S-propafenone an average of 39% higher and R-propafenone an average of 71% higher. <br><br>The mechanism for this possible interaction is likely paroxetine-mediated inhibition of propafenone 5-hydroxylation via CYP2D6. This is consistent with the known ability of paroxetine to potently inhibit CYP2D6 activity.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hemeryck A, De Vriendt C, Belpaire FM, “Effect of Selective Serotonin Reuptake Inhibitors on the Oxidative Metabolism of Propafenone: In Vitro Studies Using Human Liver Microsomes,” <i>J Clin Psychopharmacol</i>, 2000, 20(4):428-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10917404\">[PubMed 10917404]</a></p>\n<p>2. Cai WM, Chen B, Zhou Y, et al, “Fluoxetine Impairs the CYP2D6-Mediated Metabolism of Propafenone Enantiomers in Healthy Chinese Volunteers,” <i>Clin Pharmacol Ther</i>, 1999, 66(5):516-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10579479\">[PubMed 10579479]</a></p>\n<p>3. Belpaire FM, Wijnant P, Temmerman A, et al, “The Oxidative Metabolism of Metoprolol in Human Liver Microsomes: Inhibition by the Selective Serotonin Reuptake Inhibitors,” <i>Eur J Clin Pharmacol</i>, 1998, 54(3):261-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9681670\">[PubMed 9681670]</a></p>\n<p>4. Volotinen M, Korjamo T, Tolonen A, et al, “Effects of Selective Serotonin Reuptake Inhibitors on Timolol Metabolism in Human Liver Microsomes and Cryo-Preserved Hepatocytes,” <i>Basic Clin Pharmacol Toxicol</i>, 2009, Nov 11 [Epub ahead of print]. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19912165\">[PubMed 19912165]</a></p>\n<p>5. Hara Y, Nakajima M, Miyamoto KI, et al, “Inhibitory Effects of Psychotropic Drugs on Mexiletine Metabolism in Human Liver Microsomes: Prediction of In Vivo Drug Interactions,” <i>Xenobiotica</i>, 2005, 35(6):549-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16192107\">[PubMed 16192107]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5302":"<p><b>Title</b> Propafenone / Sertraline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sertraline may enhance the QTc-prolonging effect of Propafenone. Sertraline may increase the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination closely for signs and symptoms of excessive QTc interval prolongation and arrhythmia.</p> \n<p><b>Discussion</b> An in vitro study using human liver microsomes concluded that sertraline was only a moderate inhibitor of propafenone 5-hydroxylation, which is the primary route of propafenone metabolism.<sup>1</sup> Sertraline was also not a potent inhibitor of propafenone N-dealkylation, a secondary route of propafenone metabolism. However, fluoxetine and paroxetine, other selective serotonin reuptake inhibitors (SSRIs) that are more potent inhibitors of CYP2D6 than sertraline, were shown to potently inhibit propafenone 5-hydroxylation but not its N-dealkylation. <br><br>Of note, propafenone AUC was an average of 50% higher when propafenone (400 mg x1) was administered on day 10 of fluoxetine administration (20 mg/day) to 9 healthy Chinese volunteers.<sup>2</sup> Maximum serum concentrations (Cmax) of propafenone were also impacted, though in a stereoselective manner, with S-propafenone an average of 39% higher and R-propafenone an average of 71% higher. <br><br>It is uncertain whether sertraline would significantly alter propafenone concentrations or effect, but considering both the available in vitro data and the only modest effect of sertraline on CYP2D6,<sup>3,4,5</sup> no significant interaction would be expected. The mechanism for the possible interaction between propafenone and selected other SSRIs is likely paroxetine- or fluoxetine-mediated inhibition of propafenone 5-hydroxylation via CYP2D6. This is consistent with the known ability of both paroxetine and fluoxetine to potently inhibit CYP2D6 activity.<sup>3,4,5</sup><br><br>Despite the questionable potential for a pharmacokinetic interaction between these agents, their combination may theoretically increase the risk of clinically significant QTc interval prolongation and arrhythmia based on reports of these effects associated with the individual agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hemeryck A, De Vriendt C, Belpaire FM, “Effect of Selective Serotonin Reuptake Inhibitors on the Oxidative Metabolism of Propafenone: In Vitro Studies Using Human Liver Microsomes,” <i>J Clin Psychopharmacol</i>, 2000, 20(4):428-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10917404\">[PubMed 10917404]</a></p>\n<p>2. Cai WM, Chen B, Zhou Y, et al, “Fluoxetine Impairs the CYP2D6-Mediated Metabolism of Propafenone Enantiomers in Healthy Chinese Volunteers,” <i>Clin Pharmacol Ther</i>, 1999, 66(5):516-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10579479\">[PubMed 10579479]</a></p>\n<p>3. Belpaire FM, Wijnant P, Temmerman A, et al, “The Oxidative Metabolism of Metoprolol in Human Liver Microsomes: Inhibition by the Selective Serotonin Reuptake Inhibitors,” <i>Eur J Clin Pharmacol</i>, 1998, 54(3):261-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9681670\">[PubMed 9681670]</a></p>\n<p>4. Volotinen M, Korjamo T, Tolonen A, et al, “Effects of Selective Serotonin Reuptake Inhibitors on Timolol Metabolism in Human Liver Microsomes and Cryo-Preserved Hepatocytes,” <i>Basic Clin Pharmacol Toxicol</i>, 2009, Nov 11 [Epub ahead of print]. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19912165\">[PubMed 19912165]</a></p>\n<p>5. Hara Y, Nakajima M, Miyamoto KI, et al, “Inhibitory Effects of Psychotropic Drugs on Mexiletine Metabolism in Human Liver Microsomes: Prediction of In Vivo Drug Interactions,” <i>Xenobiotica</i>, 2005, 35(6):549-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16192107\">[PubMed 16192107]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5305":"<p><b>Title</b> Propafenone / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Propafenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to propafenone closely when used together with fluvoxamine, particularly watching for signs/symptoms of propafenone toxicity (including monitoring ECG for QT prolongation or other signs of pro-arrhythmia).</p> \n<p><b>Discussion</b> An in vitro study using human liver microsomes concluded that fluvoxamine was a moderate inhibitor of propafenone 5-hydroxylation, which is the primary route of propafenone metabolism.<sup>1</sup> Fluvoxamine was also the only selective serotonin reuptake inhibitor (SSRI) that significantly inhibited propafenone N-dealkylation, a secondary route of propafenone metabolism. Fluoxetine and paroxetine, SSRIs that are potent inhibitors of CYP2D6, were shown to potently inhibit propafenone 5-hydroxylation but not its N-dealkylation.<br><br>Of note, propafenone AUC was an average of 50% higher when propafenone (400 mg x1) was administered on day 10 of fluoxetine administration (20 mg/day) to 9 healthy Chinese volunteers.<sup>2</sup> Maximum serum concentrations (Cmax) of propafenone were also impacted, though in a stereoselective manner, with S-propafenone an average of 39% higher and R-propafenone an average of 71% higher. <br><br>The mechanisms for a possible fluvoxamine-propafenone interaction likely include fluvoxamine-mediated inhibition of both propafenone 5-hydroxylation via CYP2D6 and propafenone N-dealkylation via CYP1A2 and CYP3A4. This is consistent with the known ability of fluvoxamine to modestly inhibit CYP2D6 activity and to inhibit CYPs 1A2 and 3A4.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hemeryck A, De Vriendt C, Belpaire FM, “Effect of Selective Serotonin Reuptake Inhibitors on the Oxidative Metabolism of Propafenone: In Vitro Studies Using Human Liver Microsomes,” <i>J Clin Psychopharmacol</i>, 2000, 20(4):428-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10917404\">[PubMed 10917404]</a></p>\n<p>2. Cai WM, Chen B, Zhou Y, et al, “Fluoxetine Impairs the CYP2D6-Mediated Metabolism of Propafenone Enantiomers in Healthy Chinese Volunteers,” <i>Clin Pharmacol Ther</i>, 1999, 66(5):516-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10579479\">[PubMed 10579479]</a></p>\n<p>3. Belpaire FM, Wijnant P, Temmerman A, et al, “The Oxidative Metabolism of Metoprolol in Human Liver Microsomes: Inhibition by the Selective Serotonin Reuptake Inhibitors,” <i>Eur J Clin Pharmacol</i>, 1998, 54(3):261-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9681670\">[PubMed 9681670]</a></p>\n<p>4. Volotinen M, Korjamo T, Tolonen A, et al, “Effects of Selective Serotonin Reuptake Inhibitors on Timolol Metabolism in Human Liver Microsomes and Cryo-Preserved Hepatocytes,” <i>Basic Clin Pharmacol Toxicol</i>, 2009, Nov 11 [Epub ahead of print]. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19912165\">[PubMed 19912165]</a></p>\n<p>5. Prescribing information. Luvox CR (fluvoxamine). Palo Alto, CA: Jazz Pharmaceuticals, Inc., 10/2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5306":"<p><b>Title</b> Ursodiol / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to ursodiol closely when used together with any estrogen derivative.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> Ursodiol prescribing information cautions that concurrent use with estrogen may diminish the therapeutic effect of ursodiol as a result of estrogen-mediated increases in hepatic cholesterol secretion.<sup>1</sup><br><br>The precise clinical significance of this possible interaction is uncertain. The specific mechanism by which estrogens increase hepatic cholesterol secretion and increase the risk for gallstones is fairly well-described.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Urso 250 / Urso Forte (ursodiol). Birmingham, AL: Axcan Pharma US, Inc., 11/2009.</p>\n<p>2. Wang HH, Liu M, Clegg DJ, et al, “New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation,” <i>Biochim Biophys Acta</i>, 2009, 1791(11):1037-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19589396\">[PubMed 19589396]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5307":"<p><b>Title</b> Ursodiol / Fibric Acid Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fibric Acid Derivatives may diminish the therapeutic effect of Ursodiol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to ursodiol closely when used together with any fibric acid derivative.</p>\n<div>\n <p><b>Fibric Acid Derivatives Interacting Members</b> Bezafibrate, Ciprofibrate, Fenofibrate and Derivatives, Gemfibrozil</p>\n</div> \n<p><b>Discussion</b> Ursodiol prescribing information cautions that concurrent use with fibric acid derivatives may diminish the therapeutic effect of ursodiol as a result of fibrate-mediated increases in hepatic cholesterol secretion.<sup>1</sup><br><br>The precise clinical significance of this possible interaction is uncertain. The effect of fibrates on hepatic cholesterol secretion and the risk for gallstones is fairly well-described,<sup>2,3,4,5,6</sup> though there is some uncertainty regarding whether or not gemfibrozil has as great of an effect as other fibrates.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Urso 250 / Urso Forte (ursodiol). Birmingham, AL: Axcan Pharma US, Inc., 11/2009.</p>\n<p>2. Mazzella G, Bazzoli F, Villanova N, et al, “Effect of Gemfibrozil Administration on Biliary Lipid Secretion in Hyperlipidemic Patients. A Crossover Study with Clofibrate,” <i>Scand J Gastroenterol</i>, 1990, 25(12):1227-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2274744\">[PubMed 2274744]</a></p>\n<p>3. Leiss O, von Bergmann K, Gnasso A, et al, “Effect of Gemfibrozil on Biliary Lipid Metabolism in Normolipemic Subjects,” <i>Metabolism</i>, 1985, 34(1):74-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3855325\">[PubMed 3855325]</a></p>\n<p>4. Leiss O, Meyer-Krahmer K, von Bergmann K, “Biliary Lipid Secretion in Patients with Heterozygous Familial Hypercholesterolemia and Combined Hyperlipidemia. Influence of Bezafibrate and Fenofibrate,” <i>J Lipid Res</i>, 1986, 27(7):713-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3760707\">[PubMed 3760707]</a></p>\n<p>5. Okolicsanyi L, Lirussi F, Strazzabosco M, et al, “The Effect of Drugs on Bile Flow and Composition. An Overview,” <i>Drugs</i>, 1986, 31(5):430-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2872047\">[PubMed 2872047]</a></p>\n<p>6. Angelin B, Einarsson K, Leijd B, “Effect of Ciprofibrate Treatment on Biliary Lipids in Patients with Hyperlipoproteinaemia,” <i>Eur J Clin Invest</i>, 1984, 14(1):73-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6421601\">[PubMed 6421601]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5308":"<p><b>Title</b> Rosuvastatin / Gemfibrozil</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Specific recommendations regarding dose adjustment with concurrent use differ between Canadian (limit rosuvastatin to 20 mg/day) and US labeling (limit to 10 mg/day).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemfibrozil may enhance the myopathic (rhabdomyolysis) effect of Rosuvastatin. Gemfibrozil may increase the serum concentration of Rosuvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> When possible, avoid concurrent use of gemfibrozil or consider using micronized fenofibrate in patients receiving rosuvastatin. For patients in whom concomitant use of gemfibrozil can not be avoided, limit rosuvastatin to 10 mg/day (US labeling recommendation) or 20 mg/day (Canadian labeling recommendation). Monitor closely for signs and symptoms of rhabdomyolysis with concomitant use.</p> \n<p><b>Discussion</b> Since initial case reports of rhabdomyolysis in patients receiving lovastatin and gemfibrozil,<sup>1</sup> data have accumulated that make it clear that gemfibrozil considerably increases the risk of rhabdomyolysis when combined with HMG-CoA reductase inhibitors. An examination of the FDA Adverse Event Reporting System (AERS) database found that the rate of rhabdomyolysis associated with most of the HMG-CoA reductase inhibitors was increased more than 10-fold when combined with gemfibrozil.<sup>2</sup> Of the 866 cases of rhabdomyolysis in the AERS database, 384 (44%) were associated with concomitant use of gemfibrozil, and more than 50% (479 cases) involved cerivastatin, which is no longer available in the U.S. A separate study of the AERS database found that fenofibrate does not confer the same risk as gemfibrozil when used in combination with the HMG-CoA reductase inhibitors, reporting a risk of rhabdomyolysis at least 15-fold lower with fenofibrate-HMG-CoA reductase inhibitor combinations than with gemfibrozil-HMG-CoA reductase inhibitor combinations.<sup>3</sup> The precise mechanism of this interaction is uncertain, but it does appear to involve both a pharmacokinetic and pharmacodynamic component. <br><br>Administration of gemfibrozil (600 mg BID x 7 days) with rosuvastatin (80 mg single dose on day 4) in 20 healthy subjects increased rosuvastatin AUC and Cmax approximately 2-fold each and decreased N-desmethyl rosuvastatin AUC (48%) and Cmax (39%) when compared to rosuvastatin with placebo.<sup>4</sup> Rosuvastatin undergoes limited metabolism via CYP2C9 and undergoes hepatic uptake via organic anion transporting polypeptide 1B1 (OATP1B1).<sup>5,6</sup> Possible explanations for the observed interaction might include gemfibrozil-mediated inhibition of OATP1B1 or CYP2C9, or a combination of these effects. <br><br>In addition to these pharmacokinetic effects, gemfibrozil has been associated with rhabdomyolysis and other muscle toxicities as monotherapy, raising the possibility of an additional pharmacodynamic interaction. Although the risk of severe muscle toxicity associated with gemfibrozil monotherapy is small (59.6 cases of rhabdomyolysis per million prescriptions), it is considerably greater than that reported with fenofibrate monotherapy (5.5 cases per million prescriptions).<sup>7</sup><br><br>In cases where concomitant use of gemfibrozil and rosuvastatin can not be avoided, rosuvastatin dosage reductions are recommended. US labeling<sup>5</sup> and Canadian labeling<sup>8</sup> dosing recommendations differ and appropriate labeling should be consulted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce LR, Wysowski DK, and Gross TP, “Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy,” <i>JAMA</i>, 1990, 264(1):71-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2355431\">[PubMed 2355431]</a></p>\n<p>2. Chang JT, Staffa JA, Parks M, et al., “Rhabdomyolysis with HMG-CoA Reductase Inhibitors and Gemfibrozil Combination Therapy,” <i>Pharmacoepidemiol Drug Saf</i>, 2004, 13:417-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15269925\">[PubMed 15269925]</a></p>\n<p>3. Jones PH, Davidson MH, “Reporting Rate of Rhabdomyolysis with Fenofibrate + Statin Versus Gemfibrozil + Any Statin,” <i>Am J Cardiol</i>, 2005, 95:120-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15619408\">[PubMed 15619408]</a></p>\n<p>4. Schneck DW, Birmingham BK, Zalikowski JA, et al, “The Effect of Gemfibrozil on the Pharmacokinetics of Rosuvastatin,” <i>Clin Pharmacol Ther</i>, 2004, 75(5):455-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15116058\">[PubMed 15116058]</a></p>\n<p>5. Prescribing information. Crestor (rosuvastatin). Wilmington, DE: AstraZeneca Pharmaceuticals LP, February 2012.</p>\n<p>6. Neuvonen PJ, Niemi M, Backman JT, “Drug Interactions with Lipid-Lowering Drugs: Mechanisms and Clinical Relevance,” <i>Clin Pharmacol Ther</i>, 2006, 80:565-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17178259\">[PubMed 17178259]</a></p>\n<p>7. Alsheikh-Ali AA, Kuvin JT, Karas RH, “Risk of Adverse Events with Fibrates,” <i>Am J Cardiol</i>, 2004, 94:935-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15464682\">[PubMed 15464682]</a></p>\n<p>8. Prescribing information. Crestor (rosuvastatin). Mississauga, Ontario: AstraZeneca Canada Inc., October 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5309":"<p><b>Title</b> Linezolid / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Linezolid. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Prescribing information for linezolid describes a study of 16 healthy volunteers in which coadministration of rifampin (600 mg daily for 8 days) with linezolid (600 mg twice daily for 5 doses) was associated with 32% and 21% decreases in linezolid AUC and maximum serum concentration (Cmax), respectively.<sup>1,2</sup> A study in human hepatocytes similarly found that rifampin treatment was associated with a 1.3- to 1.6-fold increase in linezolid metabolism.<sup>2</sup><br><br>The mechanism of this interaction is unknown. The decrease in linezolid concentrations could be due to induction of metabolism by rifampin, but it is unclear what enzyme(s) might be involved.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zyvox (linezolid). New York, NY: Pharmacia &amp; Upjohn Company, December 2009.</p>\n<p>2. Gandelman K, Zhu T, Fahmi OA, et al, “Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism,” <i>J Clin Pharmacol</i>, 2010, Apr 6. (Epub ahead of print) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20371736\">[PubMed 20371736]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5310":"<p><b>Title</b> Pravastatin / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemfibrozil may enhance the myopathic (rhabdomyolysis) effect of Pravastatin. Gemfibrozil may increase the serum concentration of Pravastatin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concurrent use of gemfibrozil and pravastatin should be avoided. Consider using micronized fenofibrate, niacin (though pravastatin dose adjustments may be needed), or some other approach to decrease triglycerides and/or increase HDL. Regardless of chosen approach, monitor patients for signs and symptoms of rhabdomyolysis during concomitant use of pravastatin with any other lipid-altering agent.</p> \n<p><b>Discussion</b> Since initial case reports of rhabdomyolysis in patients receiving lovastatin and gemfibrozil,<sup>1</sup> data have accumulated that make it clear that gemfibrozil considerably increases the risk of rhabdomyolysis when combined with HMG-CoA reductase inhibitors. An examination of the FDA Adverse Event Reporting System (AERS) database found that the rate of rhabdomyolysis associated with most of the HMG-CoA reductase inhibitors was increased more than 10-fold when combined with gemfibrozil.<sup>2</sup> Of the 866 cases of rhabdomyolysis in the AERS database, 384 (44%) were associated with concomitant use of gemfibrozil, and more than 50% (479 cases) involved cerivastatin, which is no longer available in the U.S. A separate study of the AERS database found that fenofibrate does not confer the same risk as gemfibrozil when used in combination with the HMG-CoA reductase inhibitors, reporting a risk of rhabdomyolysis at least 15-fold lower with fenofibrate-HMG-CoA reductase inhibitor combinations than with gemfibrozil-HMG-CoA reductase inhibitor combinations.<sup>3</sup> The precise mechanism of this interaction is uncertain, but it does appear to involve both a pharmacokinetic and pharmacodynamic component. <br><br>In ten healthy subjects, administration of gemfibrozil (600 mg BID x3 days) with pravastatin (40 mg single dose on day 3), increased pravastatin AUC (2-fold) and Cmax (81%), and decreased pravastatin renal clearance (43%) compared to pravastatin with placebo.<sup>4</sup> Pravastatin undergoes hepatic uptake via organic anion transporting polypeptide 1B1 (OATP1B1)<sup>5</sup> and possible explanations for the observed interactions might include gemfibrozil mediated inhibition of OATP1B1, decreased pravastatin renal clearance, or a combination of these effects.<br><br>In addition to these pharmacokinetic effects, gemfibrozil has been associated with rhabdomyolysis and other muscle toxicities as monotherapy, raising the possibility of an additional pharmacodynamic interaction. Although the risk of severe muscle toxicity associated with gemfibrozil monotherapy is small (59.6 cases of rhabdomyolysis per million prescriptions), it is considerably greater than that reported with fenofibrate monotherapy (5.5 cases per million prescriptions).<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce LR, Wysowski DK, and Gross TP, “Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy,” <i>JAMA</i>, 1990, 264(1):71-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2355431\">[PubMed 2355431]</a></p>\n<p>2. Chang JT, Staffa JA, Parks M, et al., “Rhabdomyolysis with Hmg-Coa Reductase Inhibitors and Gemfibrozil Combination Therapy,” <i>Pharmacoepidemiol Drug Saf</i>, 2004, 13:417-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15269925\">[PubMed 15269925]</a></p>\n<p>3. Jones PH,Davidson MH, “Reporting Rate of Rhabdomyolysis with Fenofibrate + Statin Versus Gemfibrozil + Any Statin,” <i>Am J Cardiol</i>, 2005, 95:120-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15619408\">[PubMed 15619408]</a></p>\n<p>4. Kyrklund C, Backman JT, Neuvonen M, et al, “Gemfibrozil Increases Plasma Pravastatin Concentrations and Reduces Pravastatin Renal Clearance,” <i>Clin Pharmacol Ther</i>, 2003, 73(6):538-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12811363\">[PubMed 12811363]</a></p>\n<p>5. Neuvonen PJ, Niemi M,Backman JT, “Drug Interactions with Lipid-Lowering Drugs: Mechanisms and Clinical Relevance,” <i>Clin Pharmacol Ther</i>, 2006, 80:565-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17178259\">[PubMed 17178259]</a></p>\n<p>6. Alsheikh-Ali AA, Kuvin JT, Karas RH, “Risk of Adverse Events with Fibrates,” <i>Am J Cardiol</i>, 2004, 94:935-8.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5311":"<p><b>Title</b> Simvastatin / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemfibrozil may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Gemfibrozil may increase the serum concentration of Simvastatin. Concentrations of the active simvastatin acid metabolite may also be increased by gemfibrozil. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concurrent use of gemfibrozil with simvastatin is contraindicated.</p> \n<p><b>Discussion</b> Since initial case reports of rhabdomyolysis in patients receiving lovastatin and gemfibrozil,<sup>1</sup> data have accumulated that make it clear that gemfibrozil considerably increases the risk of rhabdomyolysis when combined with HMG-CoA reductase inhibitors. An examination of the FDA Adverse Event Reporting System (AERS) database found that the rate of rhabdomyolysis associated with most of the HMG-CoA reductase inhibitors was increased more than 10-fold when combined with gemfibrozil.<sup>2</sup> Of the 866 cases of rhabdomyolysis in the AERS database, 384 (44%) were associated with concomitant use of gemfibrozil, and more than 50% (479 cases) involved cerivastatin, which is no longer available in the U.S. A separate study of the AERS database found that fenofibrate does not confer the same risk as gemfibrozil when used in combination with the HMG-CoA reductase inhibitors, reporting a risk of rhabdomyolysis at least 15-fold lower with fenofibrate-HMG-CoA reductase inhibitor combinations than with gemfibrozil-HMG-CoA reductase inhibitor combinations.<sup>3</sup> The precise mechanism of this interaction is uncertain, but it does appear to involve both a pharmacokinetic and pharmacodynamic component. <br><br>In 10 healthy subjects, concurrent administration of gemfibrozil (600 mg BID x 3 days) and simvastatin (40 mg single dose on day 3) increased simvastatin AUC (35%) and half-life (74%) and simvastatin acid (active form of parent drug) AUC (approximately 3-fold), Cmax (approximately 2-fold), and half-life (51%) compared to simvastatin with placebo.<sup>4</sup> Simvastatin is metabolized by CYP3A4 and undergoes hepatic uptake via organic anion transporting polypeptide 1B1 (OATP1B1).<sup>5,6</sup> Simvastatin acid is metabolized by both CYP3A4 and CYP2C8.<sup>6,7</sup> Though not known to inhibit CYP3A4, gemfibrozil and its glucuronide inhibit OATP1B1 and CYP2C8,<sup>6</sup> and possible explanations for the observed interaction might include inhibition of this transporter or enzyme, or a combination of these effects.<br><br>In addition to these pharmacokinetic effects, gemfibrozil has been associated with rhabdomyolysis and other muscle toxicities as monotherapy, raising the possibility of an additional pharmacodynamic interaction. Although the risk of severe muscle toxicity associated with gemfibrozil monotherapy is small (59.6 cases of rhabdomyolysis per million prescriptions), it is considerably greater than that reported with fenofibrate monotherapy (5.5 cases per million prescriptions).<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce LR, Wysowski DK, and Gross TP, “Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy,” <i>JAMA</i>, 1990, 264(1):71-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2355431\">[PubMed 2355431]</a></p>\n<p>2. Chang JT, Staffa JA, Parks M, et al., “Rhabdomyolysis with Hmg-Coa Reductase Inhibitors and Gemfibrozil Combination Therapy,” <i>Pharmacoepidemiol Drug Saf</i>, 2004, 13:417-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15269925\">[PubMed 15269925]</a></p>\n<p>3. Jones PH,Davidson MH, “Reporting Rate of Rhabdomyolysis with Fenofibrate + Statin Versus Gemfibrozil + Any Statin,” <i>Am J Cardiol</i>, 2005, 95:120-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15619408\">[PubMed 15619408]</a></p>\n<p>4. Backman JT, Kyrklund C, Kivisto KT, et al, “Plasma Concentrations of Active Simvastatin Acid are Increased by Gemfibrozil,” <i>Clin Pharmacol Ther</i>, 2000, 68(2):122-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10976543\">[PubMed 10976543]</a></p>\n<p>5. Prescribing information. Zocor (simvastatin). Whitehouse Station, NJ: Merck &amp; Co., Inc., June 2011.</p>\n<p>6. Neuvonen PJ, Niemi M,Backman JT, “Drug Interactions with Lipid-Lowering Drugs: Mechanisms and Clinical Relevance,” <i>Clin Pharmacol Ther</i>, 2006, 80(6):565-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17178259\">[PubMed 17178259]</a></p>\n<p>7. Prueksaritanont T, Bennet M, and Yu N, “The Human Hepatic Metabolism of Simvastatin Hyroxy Acid is Mediated Primarily by CYP3A4, and not CYP2D6,” <i>Br J Clin Pharmacol</i>, 2003, 56:120-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12848784\">[PubMed 12848784]</a></p>\n<p>8. Alsheikh-Ali AA, Kuvin JT, Karas RH, “Risk of Adverse Events with Fibrates,” <i>Am J Cardiol</i>, 2004, 94:935-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15464682\">[PubMed 15464682]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5313":"<p><b>Title</b> ClonazePAM / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of ClonazePAM. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A single case report describes a 78-year-old patient with heart failure, stabilized on amiodarone, who developed slurred speech, confusion, dry mouth, and urinary incontinence within 2 months of starting clonazepam therapy for restless leg syndrome.<sup>1</sup> Symptoms resolved following discontinuation of clonazepam. No other information is available. The precise mechanism for this potential interaction is uncertain, though amiodarone is a known inhibitor of several cytochrome P450 enzymes, including CYP3A4, which is thought to play an important role in the metabolism of clonazepam.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Witt DM, Ellsworth AJ, and Leversee JH, “Amiodarone-Clonazepam Interaction,” <i>Ann Pharmacother</i>, 1993, 27:1463-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8305778\">[PubMed 8305778]</a></p>\n<p>2. Prescribing information. Cordarone (amiodarone). Philadelphia, PA: Wyeth Pharmaceuticals Inc., 08/2009.</p>\n<p>3. Prescribing information. Klonopin (clonazepam). Nutley, NJ: Roche Laboratories Inc., April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5314":"<p><b>Title</b> DiazePAM / Propranolol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Propranolol may increase the serum concentration of DiazePAM. Concentrations of the active metabolite desmethyldiazepam may also be increased. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Concurrent administration of diazepam (0.1 mg/kg IV) with metoprolol (100 mg twice daily) was associated with a small but statistically significant 25% increase in diazepam half-life and an average 18% decrease in diazepam clearance in a study of 6 healthy volunteers.<sup>1</sup> Similarly, concurrent metoprolol and propranolol were each associated with small but statistically significant increases in diazepam AUC and desmethyldiazepam (DMDZ, active metabolite of diazepam) concentrations in a study of 12 healthy volunteers.<sup>2</sup> Likewise, administration of diazepam (5-10 mg IV x1) with propranolol (80 mg three times daily) in healthy volunteers was associated with a statistically significant 18% increase in diazepam half-life and an average 17% increase in the AUC of DMDZ.<sup>3</sup> Another study of healthy volunteers also found a small but statistically significant increase in DMDZ (also the active metabolite of clorazepate) half-life (61 hrs vs. 55 hrs) and a corresponding 12% decrease in DMDZ clearance when clorazepate (20 mg IV x1) was administered with propranolol (80 mg twice daily).<sup>4</sup><br><br>No affects were noted when propranolol was combined with alprazolam, triazolam, lorazepam, or oxazepam,<sup>3,5,6</sup> when metoprolol was combined with lorazepam,<sup>7</sup>, when labetolol was combined with oxazepam,<sup>5</sup> or when atenolol was combined with diazepam.<sup>2</sup> The mechanism of this interaction is likely related to an inhibition of the oxidative metabolism of certain benzodiazepines, but given the small magnitude of the interaction, it is unclear if this interaction will be of any clinical significance in most patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Klotz U and Reimann IW, “Pharmacokinetic and Pharmacodynamic Interaction Study of Diazepam and Metoprolol,”<i> Eur J Clin Pharmacol</i>, 1984, 26:223-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6723761\">[PubMed 6723761]</a></p>\n<p>2. Hawksworth G, Betts T, Crowe A, et al, “Diazepam/Beta-Adrenoceptor Antagonist Interactions,” <i>Br Jr Clin Pharmacol</i>, 1984, 17:69-76S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6146341\">[PubMed 6146341]</a></p>\n<p>3. Ochs HR, Greenblatt DJ, and Verburg-Ochs B, “Propranolol Interactions With Diazepam, Lorazepam, and Alprazolam,” <i>Clin Pharmacol Ther</i>, 1984, 36:451-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6434219\">[PubMed 6434219]</a></p>\n<p>4. Ochs HR, Greenblatt DJ, Locniskar A, et al, “Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate,” <i>Klin Wochenschr</i>, 1986, 64(23):1217-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2879960\">[PubMed 2879960]</a></p>\n<p>5. Sonne J, Dossing M, Loft S, et al, “Single Dose Pharmacokinetics and Pharmacodynamics of Oral Oxazepam During Concomitant Administration of Propranolol and Labetalol,” <i>Br J Clin Pharmacol</i>, 1990, 29:33-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2297460\">[PubMed 2297460]</a></p>\n<p>6. Friedman H, Greenblatt DJ, Burstein ES, et al, “Triazolam Kinetics: Interaction with Cimetidine, Propranolol, and the Combination,” <i>J Clin Pharmacol</i>, 1988, 28(3):228-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>7. Scott AK, Cameron GA, and Hawksworth GM, “Interaction of Metoprolol With Lorazepam and Bromazepam,” <i>Eur J Clin Pharmacol</i>, 1991, 40:405-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2050176\">[PubMed 2050176]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5315":"<p><b>Title</b> Clorazepate / Propranolol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Propranolol may increase the serum concentration of Clorazepate. Concentrations of the active metabolite desmethyldiazepam may also be increased. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Concurrent administration of diazepam (0.1 mg/kg IV) with metoprolol (100 mg twice daily) was associated with a small but statistically significant 25% increase in diazepam half-life and an average 18% decrease in diazepam clearance in a study of 6 healthy volunteers.<sup>1</sup> Similarly, concurrent metoprolol and propranolol were each associated with small but statistically significant increases in diazepam AUC and desmethyldiazepam (DMDZ, active metabolite of diazepam) concentrations in a study of 12 healthy volunteers.<sup>2</sup> Likewise, administration of diazepam (5-10 mg IV x1) with propranolol (80 mg three times daily) in healthy volunteers was associated with a statistically significant 18% increase in diazepam half-life and an average 17% increase in the AUC of DMDZ.<sup>3</sup> Another study of healthy volunteers also found a small but statistically significant increase in DMDZ (also the active metabolite of clorazepate) half-life (61 hrs vs. 55 hrs) and a corresponding 12% decrease in DMDZ clearance when clorazepate (20 mg IV x1) was administered with propranolol (80 mg twice daily).<sup>4</sup><br><br>No affects were noted when propranolol was combined with alprazolam, triazolam, lorazepam, or oxazepam,<sup>3,5,6</sup> when metoprolol was combined with lorazepam,<sup>7</sup>, when labetolol was combined with oxazepam,<sup>5</sup> or when atenolol was combined with diazepam.<sup>2</sup> The mechanism of this interaction is likely related to an inhibition of the oxidative metabolism of certain benzodiazepines, but given the small magnitude of the interaction, it is unclear if this interaction will be of any clinical significance in most patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Klotz U and Reimann IW, “Pharmacokinetic and Pharmacodynamic Interaction Study of Diazepam and Metoprolol,”<i> Eur J Clin Pharmacol</i>, 1984, 26:223-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6723761\">[PubMed 6723761]</a></p>\n<p>2. Hawksworth G, Betts T, Crowe A, et al, “Diazepam/Beta-Adrenoceptor Antagonist Interactions,” <i>Br Jr Clin Pharmacol</i>, 1984, 17:69-76S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6146341\">[PubMed 6146341]</a></p>\n<p>3. Ochs HR, Greenblatt DJ, and Verburg-Ochs B, “Propranolol Interactions With Diazepam, Lorazepam, and Alprazolam,” <i>Clin Pharmacol Ther</i>, 1984, 36:451-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6434219\">[PubMed 6434219]</a></p>\n<p>4. Ochs HR, Greenblatt DJ, Locniskar A, et al, “Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate,” <i>Klin Wochenschr</i>, 1986, 64(23):1217-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2879960\">[PubMed 2879960]</a></p>\n<p>5. Sonne J, Dossing M, Loft S, et al, “Single Dose Pharmacokinetics and Pharmacodynamics of Oral Oxazepam During Concomitant Administration of Propranolol and Labetalol,” <i>Br J Clin Pharmacol</i>, 1990, 29:33-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2297460\">[PubMed 2297460]</a></p>\n<p>6. Friedman H, Greenblatt DJ, Burstein ES, et al, “Triazolam Kinetics: Interaction with Cimetidine, Propranolol, and the Combination,” <i>J Clin Pharmacol</i>, 1988, 28(3):228-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>7. Scott AK, Cameron GA, and Hawksworth GM, “Interaction of Metoprolol With Lorazepam and Bromazepam,” <i>Eur J Clin Pharmacol</i>, 1991, 40:405-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2050176\">[PubMed 2050176]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5316":"<p><b>Title</b> Clorazepate / Metoprolol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Metoprolol may increase the serum concentration of Clorazepate. Concentrations of the active metabolite desmethyldiazepam may also be increased. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Concurrent administration of diazepam (0.1 mg/kg IV) with metoprolol (100 mg twice daily) was associated with a small but statistically significant 25% increase in diazepam half-life and an average 18% decrease in diazepam clearance in a study of 6 healthy volunteers.<sup>1</sup> Similarly, concurrent metoprolol and propranolol were each associated with small but statistically significant increases in diazepam AUC and desmethyldiazepam (DMDZ, active metabolite of diazepam) concentrations in a study of 12 healthy volunteers.<sup>2</sup> Likewise, administration of diazepam (5-10 mg IV x1) with propranolol (80 mg three times daily) in healthy volunteers was associated with a statistically significant 18% increase in diazepam half-life and an average 17% increase in the AUC of DMDZ.<sup>3</sup> Another study of healthy volunteers also found a small but statistically significant increase in DMDZ (also the active metabolite of clorazepate) half-life (61 hrs vs. 55 hrs) and a corresponding 12% decrease in DMDZ clearance when clorazepate (20 mg IV x1) was administered with propranolol (80 mg twice daily).<sup>4</sup><br><br>No affects were noted when propranolol was combined with alprazolam, triazolam, lorazepam, or oxazepam,<sup>3,5,6</sup> when metoprolol was combined with lorazepam,<sup>7</sup>, when labetolol was combined with oxazepam,<sup>5</sup> or when atenolol was combined with diazepam.<sup>2</sup> The mechanism of this interaction is likely related to an inhibition of the oxidative metabolism of certain benzodiazepines, but given the small magnitude of the interaction, it is unclear if this interaction will be of any clinical significance in most patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Klotz U and Reimann IW, “Pharmacokinetic and Pharmacodynamic Interaction Study of Diazepam and Metoprolol,”<i> Eur J Clin Pharmacol</i>, 1984, 26:223-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6723761\">[PubMed 6723761]</a></p>\n<p>2. Hawksworth G, Betts T, Crowe A, et al, “Diazepam/Beta-Adrenoceptor Antagonist Interactions,” <i>Br Jr Clin Pharmacol</i>, 1984, 17:69-76S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6146341\">[PubMed 6146341]</a></p>\n<p>3. Ochs HR, Greenblatt DJ, and Verburg-Ochs B, “Propranolol Interactions With Diazepam, Lorazepam, and Alprazolam,” <i>Clin Pharmacol Ther</i>, 1984, 36:451-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6434219\">[PubMed 6434219]</a></p>\n<p>4. Ochs HR, Greenblatt DJ, Locniskar A, et al, “Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate,” <i>Klin Wochenschr</i>, 1986, 64(23):1217-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2879960\">[PubMed 2879960]</a></p>\n<p>5. Sonne J, Dossing M, Loft S, et al, “Single Dose Pharmacokinetics and Pharmacodynamics of Oral Oxazepam During Concomitant Administration of Propranolol and Labetalol,” <i>Br J Clin Pharmacol</i>, 1990, 29:33-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2297460\">[PubMed 2297460]</a></p>\n<p>6. Friedman H, Greenblatt DJ, Burstein ES, et al, “Triazolam Kinetics: Interaction with Cimetidine, Propranolol, and the Combination,” <i>J Clin Pharmacol</i>, 1988, 28(3):228-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>7. Scott AK, Cameron GA, and Hawksworth GM, “Interaction of Metoprolol With Lorazepam and Bromazepam,” <i>Eur J Clin Pharmacol</i>, 1991, 40:405-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2050176\">[PubMed 2050176]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5317":"<p><b>Title</b> DiazePAM / Metoprolol</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Metoprolol may increase the serum concentration of DiazePAM. Concentrations of the active desmethydiazepam metabolite may also be increased. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Concurrent administration of diazepam (0.1 mg/kg IV) with metoprolol (100 mg twice daily) was associated with a small but statistically significant 25% increase in diazepam half-life and an average 18% decrease in diazepam clearance in a study of 6 healthy volunteers.<sup>1</sup> Similarly, concurrent metoprolol and propranolol were each associated with small but statistically significant increases in diazepam AUC and desmethyldiazepam (DMDZ, active metabolite of diazepam) concentrations in a study of 12 healthy volunteers.<sup>2</sup> Likewise, administration of diazepam (5-10 mg IV x1) with propranolol (80 mg three times daily) in healthy volunteers was associated with a statistically significant 18% increase in diazepam half-life and an average 17% increase in the AUC of DMDZ.<sup>3</sup> Another study of healthy volunteers also found a small but statistically significant increase in DMDZ (also the active metabolite of clorazepate) half-life (61 hrs vs. 55 hrs) and a corresponding 12% decrease in DMDZ clearance when clorazepate (20 mg IV x1) was administered with propranolol (80 mg twice daily).<sup>4</sup><br><br>No affects were noted when propranolol was combined with alprazolam, triazolam, lorazepam, or oxazepam,<sup>3,5,6</sup> when metoprolol was combined with lorazepam,<sup>7</sup>, when labetolol was combined with oxazepam,<sup>5</sup> or when atenolol was combined with diazepam.<sup>2</sup> The mechanism of this interaction is likely related to an inhibition of the oxidative metabolism of certain benzodiazepines, but given the small magnitude of the interaction, it is unclear if this interaction will be of any clinical significance in most patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Klotz U and Reimann IW, “Pharmacokinetic and Pharmacodynamic Interaction Study of Diazepam and Metoprolol,”<i> Eur J Clin Pharmacol</i>, 1984, 26:223-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6723761\">[PubMed 6723761]</a></p>\n<p>2. Hawksworth G, Betts T, Crowe A, et al, “Diazepam/Beta-Adrenoceptor Antagonist Interactions,” <i>Br Jr Clin Pharmacol</i>, 1984, 17:69-76S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6146341\">[PubMed 6146341]</a></p>\n<p>3. Ochs HR, Greenblatt DJ, and Verburg-Ochs B, “Propranolol Interactions With Diazepam, Lorazepam, and Alprazolam,” <i>Clin Pharmacol Ther</i>, 1984, 36:451-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6434219\">[PubMed 6434219]</a></p>\n<p>4. Ochs HR, Greenblatt DJ, Locniskar A, et al, “Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate,” <i>Klin Wochenschr</i>, 1986, 64(23):1217-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2879960\">[PubMed 2879960]</a></p>\n<p>5. Sonne J, Dossing M, Loft S, et al, “Single Dose Pharmacokinetics and Pharmacodynamics of Oral Oxazepam During Concomitant Administration of Propranolol and Labetalol,” <i>Br J Clin Pharmacol</i>, 1990, 29:33-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2297460\">[PubMed 2297460]</a></p>\n<p>6. Friedman H, Greenblatt DJ, Burstein ES, et al, “Triazolam Kinetics: Interaction with Cimetidine, Propranolol, and the Combination,” <i>J Clin Pharmacol</i>, 1988, 28(3):228-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3360971\">[PubMed 3360971]</a></p>\n<p>7. Scott AK, Cameron GA, and Hawksworth GM, “Interaction of Metoprolol With Lorazepam and Bromazepam,” <i>Eur J Clin Pharmacol</i>, 1991, 40:405-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2050176\">[PubMed 2050176]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5319":"<p><b>Title</b> Quinagolide / Antipsychotic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antipsychotic Agents may diminish the therapeutic effect of Quinagolide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of inadequate quinagolide clinical response when used together with dopamine antagonists such as the antipsychotic agents. Individual antipsychotic agents have different activities at D2 receptors, so the magnitude of this interaction may vary according to specific antipsychotic agent.</p>\n<div>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, CloZAPine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Specific data/studies regarding this potential interaction are not available. However, quinagolide works by acting as an agonist for the D2 receptor, meaning that drugs acting as dopamine antagonists (at the D2 receptor in particular) could, in theory, diminish the clinical response to quinagolide. Quinagolide product labeling states that a reduction of the therapeutic effect of quinagolide could be expected when drugs with strong dopamine antagonist properties are used concomitantly.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5320":"<p><b>Title</b> Quinagolide / Metoclopramide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Metoclopramide may diminish the therapeutic effect of Quinagolide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs/symptoms of inadequate quinagolide clinical response when used together with dopamine antagonists such as metoclopramide.</p> \n<p><b>Discussion</b> Specific data/studies regarding this potential interaction are not available. However, quinagolide works by acting as an agonist for the D2 receptor, meaning that drugs acting as dopamine antagonists (at the D2 receptor in particular) could, in theory, diminish the clinical response to quinagolide. Quinagolide product labeling states that a reduction of the therapeutic effect of quinagolide could be expected when drugs with strong dopamine antagonist properties are used concomitantly.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5321":"<p><b>Title</b> Digoxin / Sodium Polystyrene Sulfonate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sodium Polystyrene Sulfonate may enhance the adverse/toxic effect of Digoxin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to digoxin closely in any patients receiving this combination, and monitor particularly closely for signs/symptoms of digoxin toxicity, which can occur with therapeutic serum digoxin concentrations in the setting of hypokalemia.</p> \n<p><b>Discussion</b> Sodium polystyrene sulfonate (SPS) prescribing information cautions that SPS-induced reduction of serum potassium concentrations may exacerbate the adverse cardiovascular effects of digoxin.<sup>1</sup> Of note, published reports describe several case reports of digoxin toxicity with normal serum digoxin concentrations in patients with hypokalemia.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Kayexalate (sodium polystyrene sulfonate). Bridgewater, NJ: sanofi-aventis U.S. LLC, 2009.</p>\n<p>2. Gomez-Arnau J, Maseda J, Burgos R, et al, “Cardiac arrest due to digitalis intoxication with normal serum digoxin levels: effects of hypokalemia,” <i>Drug Intell Clin Pharm</i>, 1982, 16(2):160-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7075468\">[PubMed 7075468]</a></p>\n<p>3. Steiness E, Olesen KH, “Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy,” <i>Br Heart J</i>, 1976, 38(2):167-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1259829\">[PubMed 1259829]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5322":"<p><b>Title</b> Paliperidone / RisperiDONE</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RisperiDONE may enhance the adverse/toxic effect of Paliperidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Additive paliperidone exposure is expected with this combination. Consider using an alternative combination when possible.</p> \n<p><b>Discussion</b> Paliperidone is 9-OH-risperidone, which is the active metabolite of risperidone. Concurrent use of risperidone and paliperidone would be expected to significantly increase paliperidone exposure, possibly increasing the risk of toxicity. Paliperidone prescribing information cautions that there are no available data on the combination.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invega (paliperidone). Titusville, NJ: Ortho-McNeil-Janssen, Inc., July 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5325":"<p><b>Title</b> Sirolimus / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Sirolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor sirolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change. Dose adjustment of sirolimus may be required.</p> \n<p><b>Discussion</b> Efavirenz prescribing information cautions that decreased sirolimus exposure may be expected with concurrent efavirenz and that sirolimus dose adjustment may be necessary.<sup>1</sup> The likely mechanism of this interaction is induction of the CYP3A-mediated metabolism of sirolimus by efavirenz, which is a known inducer of CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb Company, September 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5326":"<p><b>Title</b> Everolimus / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Everolimus. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor everolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change. Dose adjustment of everolimus may be required.</p> \n<p><b>Discussion</b> Efavirenz prescribing information cautions that decreased everolimus exposure may be expected with concurrent efavirenz and that everolimus dose adjustment may be necessary.<sup>1</sup> The likely mechanism of this interaction is induction of the CYP3A-mediated metabolism of everolimus by efavirenz, which is a known inducer of CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb Company, September 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5327":"<p><b>Title</b> CycloSPORINE (Systemic) / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase monitoring of cyclosporine concentrations when starting, stopping, or adjusting doses of concurrent efavirenz, particularly within the first 2 weeks. Cyclosporine dose adjustment may be required.</p> \n<p><b>Discussion</b> A case report describes a 61% decrease in cyclosporine serum concentrations approximately 1 week after initiation of an antiretroviral regimen consisting of efavirenz 600 mg/day, zidovudine 300 mg twice daily, and lamivudine 150 mg twice daily in a 39 year old.<sup>1</sup> Similarly, an observational study of 31 patients receiving both cyclosporine and either efavirenz or nevirapine found that patients receiving efavirenz (n=20) required cyclosporine doses an average of 46% higher at week 2 and 90% higher at week 12, compared to those patients receiving nevirapine.<sup>2</sup> Average dose-adjusted cyclosporine minimum serum concentrations were also 50-60% lower with concurrent efavirenz.<br><br>Consistent with these findings, efavirenz prescribing information cautions that decreased cyclosporine exposure may be expected with concurrent efavirenz and that cyclosporine dose adjustment may be necessary.<sup>3</sup><br><br>The likely mechanism of this interaction is induction of the CYP3A-mediated metabolism of cyclosporine by efavirenz, which is a known inducer of CYP3A4.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tseng A, Nguyen ME, Cardella C, et al, “Probable Interaction Between Efavirenz and Cyclosporine,” <i>AIDS</i>, 2002, 16(3):505-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11834972\">[PubMed 11834972]</a></p>\n<p>2. Frassetto LA, Browne M, Cheng A, et al, “Immunosuppressant Pharmacokinetics and Dosing Modifications in HIV-1 Infected Liver and Kidney Transplant Recipients,” <i>Am J Transplant</i>, 2007, 7(12):2816-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17949460\">[PubMed 17949460]</a></p>\n<p>3. Prescribing information. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb Company, September 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5328":"<p><b>Title</b> Tacrolimus (Systemic) / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Closely monitor tacrolimus serum concentrations when starting, stopping, or changing doses of efavirenz, particularly during the first 2 weeks after any change. Dose adjustment of tacrolimus may be required.</p> \n<p><b>Discussion</b> Efavirenz prescribing information cautions that decreased tacrolimus exposure may be expected with concurrent efavirenz and that tacrolimus dose adjustment may be necessary.<sup>1</sup> In contrast, an observational study of 4 patients found that little change was required in tacrolimus dosing after starting concurrent efavirenz.<sup>2</sup><br><br>The likely mechanism of this interaction is induction of the CYP3A-mediated metabolism of tacrolimus by efavirenz, which is a known inducer of CYP3A4.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sustiva (efavirenz). Princeton, NJ: Bristol-Myers Squibb Company, September 2009.</p>\n<p>2. Teicher E, Vincent I, Bonhomme-Faivre L, et al, “Effect of Highly Active Antiretroviral Therapy on Tacrolimus Pharmacokinetics in Hepatitis C Virus and HIV Co-Infected Liver Transplant Recipients in the ANRS HC-08 Study,” <i>Clin Pharmacokinet</i>, 2007, 46(11):941-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17922559\">[PubMed 17922559]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5329":"<p><b>Title</b> Lovastatin / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemfibrozil may enhance the myopathic (rhabdomyolysis) effect of Lovastatin. Gemfibrozil may increase the serum concentration of Lovastatin. More specifically, gemfibrozil may increase the serum concentrations of lovastatin acid (active form of parent drug). <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Avoid concomitant use of lovastatin and gemfibrozil.</p> \n<p><b>Discussion</b> Since initial case reports of rhabdomyolysis in patients receiving lovastatin and gemfibrozil,<sup>1</sup> data have accumulated that make it clear that gemfibrozil considerably increases the risk of rhabdomyolysis when combined with HMG-CoA reductase inhibitors. An examination of the FDA Adverse Event Reporting System (AERS) database found that the rate of rhabdomyolysis associated with most of the HMG-CoA reductase inhibitors was increased more than 10-fold when combined with gemfibrozil.<sup>2</sup> Of the 866 cases of rhabdomyolysis in the AERS database, 384 (44%) were associated with concomitant use of gemfibrozil, and more than 50% (479 cases) involved cerivastatin, which is no longer available in the U.S. A separate study of the AERS database found that fenofibrate does not confer the same risk as gemfibrozil when used in combination with the HMG-CoA reductase inhibitors, reporting a risk of rhabdomyolysis at least 15-fold lower with fenofibrate-HMG-CoA reductase inhibitor combinations than with gemfibrozil-HMG-CoA reductase inhibitor combinations.<sup>3</sup> The precise mechanism of this interaction is uncertain, but it does appear to involve both a pharmacokinetic and pharmacodynamic component. <br><br>In a randomized, 3-phase crossover study of 11 healthy subjects receiving gemfibrozil 600 mg BID (gemfibrozil phase), bezafibrate 40 mg QD (bezafibrate phase), or placebo (control phase) for 3 days with lovastatin (40 mg single dose on day 3 of each phase), lovastatin acid (active form of parent drug) AUC and Cmax increased approximately 3-fold each with gemfibrozil when compared to placebo.<sup>4</sup> Significant changes in lovastatin AUC or Cmax were not observed with gemfibrozil, while bezafibrate had no significant effect on the pharmacokinetics of either parent drug or acid form when compared to placebo. Lovastatin is metabolized by CYP3A4 and undergoes hepatic uptake via organic anion transporting polypeptide 1B1 (OATP1B1).<sup>5,6</sup> Lovastatin acid is presumed to be metabolized by CYP3A4 and CYP2C8.<sup>5,6</sup> Though not known to inhibit CYP3A4, gemfibrozil and its glucuronide inhibit OATP1B1 and CYP2C8,<sup>6</sup> and possible explanations for the observed interaction might include inhibition of this transporter or enzyme, or a combination of these effects.<br><br>In addition to these pharmacokinetic effects, gemfibrozil has been associated with rhabdomyolysis and other muscle toxicities as monotherapy, raising the possibility of an additional pharmacodynamic interaction. Although the risk of severe muscle toxicity associated with gemfibrozil monotherapy is small (59.6 cases of rhabdomyolysis per million prescriptions), it is considerably greater than that reported with fenofibrate monotherapy (5.5 cases per million prescriptions).<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce LR, Wysowski DK, and Gross TP, “Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy,” <i>JAMA</i>, 1990, 264(1):71-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2355431\">[PubMed 2355431]</a></p>\n<p>2. Chang JT, Staffa JA, Parks M, et al., “Rhabdomyolysis with Hmg-Coa Reductase Inhibitors and Gemfibrozil Combination Therapy,” <i>Pharmacoepidemiol Drug Saf</i>, 2004, 13:417-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15269925\">[PubMed 15269925]</a></p>\n<p>3. Jones PH,Davidson MH, “Reporting Rate of Rhabdomyolysis with Fenofibrate + Statin Versus Gemfibrozil + Any Statin,” <i>Am J Cardiol</i>, 2005, 95:120-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15619408\">[PubMed 15619408]</a></p>\n<p>4. Kyrklund C, Backman JT, Kivisto KT, et al, “Plasma Concentrations of Active Lovastatin Acid are Markedly Increased by Gemfibrozil but not by Bezafibrate,” <i>Clin Pharmacol Ther</i>, 2001, 69(5):340-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11372002\">[PubMed 11372002]</a></p>\n<p>5. Prescribing information. Mevacor (lovastatin). Whitehouse Station, NJ: Merck &amp; Co., Inc., 2/2012.</p>\n<p>6. Neuvonen PJ, Niemi M,Backman JT, “Drug Interactions with Lipid-Lowering Drugs: Mechanisms and Clinical Relevance,” <i>Clin Pharmacol Ther</i>, 2006, 80(6):565-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17178259\">[PubMed 17178259]</a></p>\n<p>7. Alsheikh-Ali AA, Kuvin JT, Karas RH, “Risk of Adverse Events with Fibrates,” <i>Am J Cardiol</i>, 2004, 94:935-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15464682\">[PubMed 15464682]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5330":"<p><b>Title</b> Imatinib / Ginseng (Panax)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ginseng (Panax) may increase the serum concentration of Imatinib. <b>Severity</b> Major <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor patients closely for signs/symptoms of imatinib toxicity when used in combination with Panax ginseng.</p> \n<p><b>Discussion</b> A case report describes a 26 year old man who presented with acute lobular hepatitis attributed to imatinib-induced liver dysfunction.<sup>1</sup> Of note, the patient had been treated with imatinib for 7 years with no prior problems, but for approximately 3 months prior to this event, the patient had been consuming energy drinks containing Panax ginseng, causing the authors to hypothesize that the ginseng could have contributed to this adverse reaction.<sup>1</sup> Imatinib was later restarted (without Panax ginseng) after resolution of the hepatic dysfunction with no problems.<br><br>The exact mechanism of this possible interaction is unclear, though the authors of the report attributed the interaction to ginseng-mediated inhibition of the CYP3A4 metabolism of imatinib.<sup>1</sup> It is important to clarify, however, that the degree to which ginseng can inhibit CYP3A activity is uncertain, with some studies reporting that ginseng constituents and/or metabolites are capable of inhibiting CYP3A,<sup>2,3,4,5</sup> but other studies finding no evidence that ginseng is capable of significant CYP3A inhibition.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bilgi N, Bell K, Ananthakrishnan AN, et al, “Imatinib and Panax Ginseng: A Potential Interaction Resulting in Liver Toxicity,” <i>Ann Pharmacother</i>, 2010, Mar 23. (Epub ahead of print) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20332334\">[PubMed 20332334]</a></p>\n<p>2. Etheridge AS, Black SR, Patel PR, et al, “An In Vitro Evaluation of Cytochrome P450 Inhibition and P-glycoprotein Interaction with Goldenseal, Ginkgo Biloba, Grape Seed, Milk Thistle, and Ginseng Extracts and their Constituents,” <i>Planta Med</i>, 2007, 73(8):731-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17611934\">[PubMed 17611934]</a></p>\n<p>3. Liu Y, Zhang JW, Li W, et al, “Ginsenoside Metabolites, Rather than Naturally Occurring Ginsenosides, Lead to Inhibition of Human Cytochrome P450 Enzymes,” <i>Toxicol Sci</i>, 2006, 91(2):356-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16547074\">[PubMed 16547074]</a></p>\n<p>4. Liu Y, Ma H, Zhang JW, et al, “Influence of Ginsenoside Rh1 and F1 on Human Cytochrome p450 Enzymes,” <i>Planta Med</i>, 2006, 72(2):126-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16491447\">[PubMed 16491447]</a></p>\n<p>5. He N, Edeki T, “The Inhibitory Effects of Herbal Components on CYP2C9 and CYP3A4 Catalytic Activities in Human Liver Microsomes,” <i>Am J Ther</i>, 2004, 11(3):206-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15133536\">[PubMed 15133536]</a></p>\n<p>6. Wanwimolruk S, Wong K, Wanwimolruk P, “Variable Inhibitory Effect of Different Brands of Commercial Herbal Supplements on Human Cytochrome P-450 CYP3A4,” <i>Drug Metabol Drug Interact</i>, 2009, 24(1):17-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19353999\">[PubMed 19353999]</a></p>\n<p>7. Gurley BJ, Gardner SF, Hubbard MA, et al, “Clinical Assessment of Effects of Botanical Supplementation on Cytochrome P450 Phenotypes in the Elderly: St John's Wort, Garlic Oil, Panax Ginseng and Ginkgo Biloba,” <i>Drugs Aging</i>, 2005, 22(6):525-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15974642\">[PubMed 15974642]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5331":"<p><b>Title</b> Pramipexole / RaNITIdine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> RaNITIdine may increase the serum concentration of Pramipexole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Pramipexole prescribing information cautions that drugs that are substrates or inhibitors of cationic transport systems (specific agents listed in prescribing information include cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine, cisplatin, and procainamide) may interfere with the elimination of pramipexole, which is also a substrate for cationic transporters,<sup>1,2</sup> citing the results from a population study showing that concurrent use with such drugs was associated with an average 20% decrease in pramipexole oral clearance.<sup>1</sup> The extent to which such a decrease in clearance would impact serum concentrations/AUC and/or be of clinical significance is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Mirapex ER</i> (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>2. Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. <i>Drug Metab Dispos</i>. 2005;33(4):495-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640376\">[PubMed 15640376]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5332":"<p><b>Title</b> Pramipexole / DilTIAZem</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> DilTIAZem may increase the serum concentration of Pramipexole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Pramipexole prescribing information cautions that drugs that are substrates or inhibitors of cationic transport systems (specific agents listed in prescribing information include cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine, cisplatin, and procainamide) may interfere with the elimination of pramipexole, which is also a substrate for cationic transporters,<sup>1,2</sup> citing the results from a population study showing that concurrent use with such drugs was associated with an average 20% decrease in pramipexole oral clearance.<sup>1</sup> The extent to which such a decrease in clearance would impact serum concentrations/AUC and/or be of clinical significance is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Mirapex ER</i> (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>2. Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. <i>Drug Metab Dispos</i>. 2005;33(4):495-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640376\">[PubMed 15640376]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5333":"<p><b>Title</b> Pramipexole / Triamterene</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Triamterene may increase the serum concentration of Pramipexole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Pramipexole prescribing information cautions that drugs that are substrates or inhibitors of cationic transport systems (specific agents listed in prescribing information include cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine, cisplatin, and procainamide) may interfere with the elimination of pramipexole, which is also a substrate for cationic transporters,<sup>1,2</sup> citing the results from a population study showing that concurrent use with such drugs was associated with an average 20% decrease in pramipexole oral clearance.<sup>1</sup> The extent to which such a decrease in clearance would impact serum concentrations/AUC and/or be of clinical significance is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Mirapex ER</i> (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>2. Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. <i>Drug Metab Dispos</i>. 2005;33(4):495-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640376\">[PubMed 15640376]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5334":"<p><b>Title</b> Pramipexole / Verapamil</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Verapamil may increase the serum concentration of Pramipexole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Pramipexole prescribing information cautions that drugs that are substrates or inhibitors of cationic transport systems (specific agents listed in prescribing information include cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine, cisplatin, and procainamide) may interfere with the elimination of pramipexole, which is also a substrate for cationic transporters,<sup>1,2</sup> citing the results from a population study showing that concurrent use with such drugs was associated with an average 20% decrease in pramipexole oral clearance.<sup>1</sup> The extent to which such a decrease in clearance would impact serum concentrations/AUC and/or be of clinical significance is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Mirapex ER</i> (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>2. Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. <i>Drug Metab Dispos</i>. 2005;33(4):495-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640376\">[PubMed 15640376]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5335":"<p><b>Title</b> Pramipexole / QuiNINE</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> QuiNINE may increase the serum concentration of Pramipexole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Pramipexole prescribing information cautions that drugs that are substrates or inhibitors of cationic transport systems (specific agents listed in prescribing information include cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine, cisplatin, and procainamide) may interfere with the elimination of pramipexole, which is also a substrate for cationic transporters,<sup>1,2</sup> citing the results from a population study showing that concurrent use with such drugs was associated with an average 20% decrease in pramipexole oral clearance.<sup>1</sup> The extent to which such a decrease in clearance would impact serum concentrations/AUC and/or be of clinical significance is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Mirapex ER</i> (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>2. Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. <i>Drug Metab Dispos</i>. 2005;33(4):495-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640376\">[PubMed 15640376]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5336":"<p><b>Title</b> Pramipexole / QuiNIDine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> QuiNIDine may increase the serum concentration of Pramipexole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Pramipexole prescribing information cautions that drugs that are substrates or inhibitors of cationic transport systems (specific agents listed in prescribing information include cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine, cisplatin, and procainamide) may interfere with the elimination of pramipexole, which is also a substrate for cationic transporters,<sup>1,2</sup> citing the results from a population study showing that concurrent use with such drugs was associated with an average 20% decrease in pramipexole oral clearance.<sup>1</sup> The extent to which such a decrease in clearance would impact serum concentrations/AUC and/or be of clinical significance is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Mirapex ER</i> (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>2. Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. <i>Drug Metab Dispos</i>. 2005;33(4):495-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640376\">[PubMed 15640376]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5337":"<p><b>Title</b> Pramipexole / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Pramipexole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients more closely for signs/symptoms of pramipexole toxicity when used together with cimetidine.</p> \n<p><b>Discussion</b> Pramipexole AUC was increased an average of 50% when administered with cimetidine (n=12), and pramipexole half-life was an average of 40% greater with cimetidine according to pramipexole prescribing information.<sup>1</sup><br><br>The specific mechanism of this interaction appears to be inhibition of pramipexole renal tubular section by cimetidine, which is a known inhibitor of certain organic cation transporters. Pramipexole prescribing information cautions that drugs that are substrates or inhibitors of cationic transport systems (specific agents listed in prescribing information include cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine, cisplatin, and procainamide) may interfere with the elimination of pramipexole, which is also a substrate for cationic transporters,<sup>1,2</sup> citing the results from a population study showing that concurrent use with such drugs was associated with an average 20% decrease in pramipexole oral clearance.<sup>1</sup> The extent to which such a decrease in clearance would impact serum concentrations/AUC and/or be of clinical significance is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Mirapex ER</i> (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>2. Ishiguro N, Saito A, Yokoyama K, et al. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. <i>Drug Metab Dispos</i>. 2005;33(4):495-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640376\">[PubMed 15640376]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5338":"<p><b>Title</b> Fluvastatin / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemfibrozil may enhance the myopathic (rhabdomyolysis) effect of Fluvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concurrent use of gemfibrozil and fluvastatin should be avoided. Consider using micronized fenofibrate, niacin (though fluvastatin dose adjustments may be needed), or some other approach to decrease triglycerides and/or increase HDL. Regardless of chosen approach, monitor patients for signs and symptoms of rhabdomyolysis during concomitant use of fluvastatin with any other lipid-altering agent.</p> \n<p><b>Discussion</b> Since initial case reports of rhabdomyolysis in patients receiving lovastatin and gemfibrozil,<sup>1</sup> data have accumulated that make it clear that gemfibrozil considerably increases the risk of rhabdomyolysis when combined with HMG-CoA reductase inhibitors. An examination of the FDA Adverse Event Reporting System (AERS) database found that the rate of rhabdomyolysis associated with most of the HMG-CoA reductase inhibitors was increased more than 10-fold when combined with gemfibrozil.<sup>2</sup> Of the 866 cases of rhabdomyolysis in the AERS database, 384 (44%) were associated with concomitant use of gemfibrozil, and more than 50% (479 cases) involved cerivastatin, which is no longer available in the U.S. A separate study of the AERS database found that fenofibrate does not confer the same risk as gemfibrozil when used in combination with the HMG-CoA reductase inhibitors, reporting a risk of rhabdomyolysis at least 15-fold lower with fenofibrate-HMG-CoA reductase inhibitor combinations than with gemfibrozil-HMG-CoA reductase inhibitor combinations.<sup>3</sup> The precise mechanism of this interaction is uncertain, but it does appear to involve both a pharmacokinetic and pharmacodynamic component.<br><br>Some small studies have failed to demonstrate any significant pharmacokinetic or pharmacodynamic interactions with concomitant use of fluvastatin and gemfibrozil;<sup>4,5</sup> however, a case report describes severe rhabdomyolysis and hepatocellular injury in a 56 year old female approximately one month after initiating concomitant fluvastatin (80 mg/day) and gemfibrozil (1200 mg/day).<sup>6</sup> Fluvastatin is primarily metabolized by CYP2C9<sup>7</sup> and is suggested to undergo limited hepatic uptake via organic anion transporting polypeptide 1B1 (OATP1B1).<sup>8</sup> Gemfibrozil inhibits CYP2C9 in vitro,<sup>9</sup> though limited pharmacokinetic effects on CYP2C9 substrates have been observed in vivo.<sup>10,11,12</sup> Gemfibrozil and its glucuronide also inhibit OATP1B1.<sup>8</sup> The explanation for the apparent lack of a pharmacokinetic interaction between fluvastatin and gemfibrozil may be related to fluvastatin's limited dependence on OATP1B1 transport.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce LR, Wysowski DK, and Gross TP, “Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy,” <i>JAMA</i>, 1990, 264(1):71-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2355431\">[PubMed 2355431]</a></p>\n<p>2. Chang JT, Staffa JA, Parks M, et al., “Rhabdomyolysis with Hmg-Coa Reductase Inhibitors and Gemfibrozil Combination Therapy,” <i>Pharmacoepidemiol Drug Saf</i>, 2004, 13:417-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15269925\">[PubMed 15269925]</a></p>\n<p>3. Jones PH,Davidson MH, “Reporting Rate of Rhabdomyolysis with Fenofibrate + Statin Versus Gemfibrozil + Any Statin,” <i>Am J Cardiol</i>, 2005, 95:120-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15619408\">[PubMed 15619408]</a></p>\n<p>4. Spence JD, Munoz CE, Hendricks L, et al, “Pharmacokinetics of the Combination of Fluvastatin and Gemfibrozil,” <i>Am J Cardiol</i>, 1995, 76(2):80-3A. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7604806\">[PubMed 7604806]</a></p>\n<p>5. Smit JW, Jansen GH, de Bruin TW, et al, “Treatment of Combined Hyperlipidaemia With Fluvastatin and Gemfibrozil, Alone or in Combination, Does Not Induce Muscle Damage,” <i>Am J Cardiol</i>, 1995, 76(2):126-8A. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7604787\">[PubMed 7604787]</a></p>\n<p>6. Akoglu H, Yilmaz R, Kirkpantur A, et al, “Combined Organ Failure with Combination Antihyperlipidemic Treatment: A Case of Hepatic Injury and Acute Renal Failure,” <i>Ann Pharmacother</i>, 2007, 41(1):143-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17148651\">[PubMed 17148651]</a></p>\n<p>7. Prescribing information. Lescol (fluvastatin). East Hanover, NJ: Novartis Pharmaceuticals Corp., 02/2012.</p>\n<p>8. Neuvonen PJ, Niemi M, Backman JT, “Drug Interactions with Lipid-Lowering Drugs: Mechanisms and Clinical Relevance,” <i>Clin Pharmacol Ther</i>, 2006, 80:565-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17178259\">[PubMed 17178259]</a></p>\n<p>9. Wen X, Wang JS, Backman J, et al, “Gemfibrozil is a Potent Inhibitor of Human Cytochrome P450 2C9,” <i>Drug Metab Dispos</i>, 2001, 29(11):1359-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11602509\">[PubMed 11602509]</a></p>\n<p>10. Niemi M, Neuvonen PJ, Kivisto KT, “Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of Glimepiride,” <i>Clin Pharmacol Ther</i>, 2001, 70(5):439-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11719730\">[PubMed 11719730]</a></p>\n<p>11. Niemi M, Backman JT, Juntti-Patinen L, et al, “Coadministration of Gemfibrozil and Itraconazole Has Only a Minor Effect on the Pharmacokinetics of the CYP2C9 and CYP3A4 Substrate Nateglinide,” <i>Br J Clin Pharmacol</i>, 2005, 60(2):208-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16042675\">[PubMed 16042675]</a></p>\n<p>12. Lilja JJ, Backman JT, Neuvonen PJ, “Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of Racemic Warfarin in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2005, 59(4):433-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15801938\">[PubMed 15801938]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5339":"<p><b>Title</b> AtorvaSTATin / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemfibrozil may enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. Gemfibrozil may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Atorvastatin labeling states that concurrent use of gemfibrozil and atorvastatin should be avoided. An American Heart Association scientific statement says that this combination may be considered if fenofibrate products are not an option. Consider using micronized fenofibrate, niacin (though atorvastatin dose adjustments may be needed), or some other approach to decrease triglycerides and/or increase HDL when clinically and otherwise appropriate. Regardless of chosen approach, monitor patients for signs and symptoms of rhabdomyolysis during concomitant use of atorvastatin with any other lipid-altering agent.</p> \n<p><b>Discussion</b> Since initial case reports of rhabdomyolysis in patients receiving lovastatin and gemfibrozil,<sup>1</sup> data have accumulated that make it clear that gemfibrozil considerably increases the risk of rhabdomyolysis when combined with HMG-CoA reductase inhibitors. An examination of the FDA Adverse Event Reporting System (AERS) database found that the rate of rhabdomyolysis associated with most of the HMG-CoA reductase inhibitors was increased more than 10-fold when combined with gemfibrozil.<sup>2</sup> Of the 866 cases of rhabdomyolysis in the AERS database, 384 (44%) were associated with concomitant use of gemfibrozil, and more than 50% (479 cases) involved cerivastatin, which is no longer available in the U.S. A separate study of the AERS database found that fenofibrate does not confer the same risk as gemfibrozil when used in combination with the HMG-CoA reductase inhibitors, reporting a risk of rhabdomyolysis at least 15-fold lower with fenofibrate-HMG-CoA reductase inhibitor combinations than with gemfibrozil-HMG-CoA reductase inhibitor combinations.<sup>3</sup> The precise mechanism of this interaction is uncertain, but it does appear to involve both a pharmacokinetic and pharmacodynamic component.<br><br>Atorvastatin prescribing information notes a 35% increase in atorvastatin AUC when administered as a 40 mg single dose concomitantly with gemfibrozil (600 mg BID for 7 days).<sup>4</sup> In 10 healthy subjects, administration of gemfibrozil (600 mg BID for 5 days) with atorvastatin (20 mg as single dose on day 3), increased the AUC of atorvastatin (24%) and its metabolites (28% to 82%) when compared to atorvastatin plus placebo.<sup>5</sup> The authors of a single case report describe rhabdomyolysis in a 43-year-old woman receiving concomitant gemfibrozil (600 mg BID) and atorvastatin (10 mg BID) and conclude that onset of rhabdomyolysis was associated with the combination.<sup>6</sup> As monotherapy with HMG-CoA reductase inhibitors and gemfibrozil has been associated with myotoxicity, it would seem prudent to closely monitor patients receiving concomitant therapy with these agents for possible cumulative effects. Given the relatively lower magnitude pharmacokinetic change associated with this interaction, an American Heart Association scientific statement suggests this combination may be considered when use of a fenofibrate product is not a reasonable alternative.<sup>7</sup><br><br>Atorvastatin is metabolized primarily by CYP3A44 and undergoes hepatic uptake via organic anion transporting polypeptide 1B1 (OATP1B1).<sup>8</sup> Though not known to inhibit CYP3A4, gemfibrozil and its glucuronide inhibit OATP1B1 providing a possible explanation for the pharmacokinetic interaction observed with atorvastatin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. <i>JAMA</i>. 1990;264(1):71-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2355431\">[PubMed 2355431]</a></p>\n<p>2. Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with Hmg-Coa reductase inhibitors and gemfibrozil combination therapy. <i>Pharmacoepidemiol Drug Saf</i>. 2004;13:417-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15269925\">[PubMed 15269925]</a></p>\n<p>3. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any Statin. <i>Am J Cardiol</i>. 2005;95:120-122. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15619408\">[PubMed 15619408]</a></p>\n<p>4. Lipitor (atorvastatin) [prescribing information]. New York, NY: Pfizer Inc; June 2017.</p>\n<p>5. Backman JT, Luurila H, Neuvonen M, et al. Rifampin markedly decreases and gemfibrozil increased the plasma concentrations of atorvastatin and its metabolites. <i>Clin Pharmacol Ther</i>. 2005;78(2):154-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16084850\">[PubMed 16084850]</a></p>\n<p>6. Duell PB, Connor WE, Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. <i>Am J Cardiol</i>. 1998;81(3):368-369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9468088\">[PubMed 9468088]</a></p>\n<p>7. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(21):e468-e495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27754879\">[PubMed 27754879]</a></p>\n<p>8. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. <i>Clin Pharmacol Ther</i>. 2006;80:565-581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17178259\">[PubMed 17178259]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5340":"<p><b>Title</b> Carmustine / Melphalan</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Melphalan may enhance the adverse/toxic effect of Carmustine. Specifically, melphalan may sensitize patients to carmustine lung toxicity. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased lung toxicity of carmustine when given in combination with melphalan.</p> \n<p><b>Discussion</b> Prescribing information for intravenous melphalan states that the drug may decrease the threshold for carmustine (BCNU) lung toxicity.<sup>1,2</sup> <br><br>An interaction between melphalan and carmustine may be the result of additive pulmonary toxicity of the agents. Although oral melphalan prescribing information does not carry a warning regarding BCNU sensitization, monitoring may still be appropriate as lung toxicity has been reported following oral administration of the drug.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Alkeran (melphalan hydrochloride) for injection [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2011.</p>\n<p>2. Evomela (melphalan) [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals, Inc.; March 2016.</p>\n<p>3. Alkeran (melphalan) tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5341":"<p><b>Title</b> Mepivacaine / Beta-Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta-Blockers may increase the serum concentration of Mepivacaine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients for increased mepivacaine effects when used concurrently with a beta-blocker.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Mepivacaine maximum serum concentrations (Cmax) were increased an average of 86% when mepivacaine (51 mg) was administered after propranolol (30 mg) in a study of 10 subjects.<sup>1</sup> The authors of the study conclude that despite this interaction, concurrent use of mepivacaine should still be safe.<br><br>The specific mechanism of this interaction is unclear. A similar interaction has been reported with the amide anesthetics lidocaine and bupivacaine.<sup>2,3,4,5,6</sup> Whether this interaction is limited to propranolol or extends to other beta-blockers is also unclear, as data regarding the interaction between lidocaine and other beta-blockers are somewhat mixed.<sup>2,3,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Popescu SM, Nechifor M, Baniceru M, et al, “Effect of Propranolol on Mepivacaine Serum Concentrations in Dental Practice,” <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>, 2008, 105(4):e19-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18329563\">[PubMed 18329563]</a></p>\n<p>2. Schneck DW, Luderer JR, Davis D, et al, “Effects of Nadolol and Propranolol on Plasma Lidocaine Clearance,” <i>Clin Pharmacol Ther</i>, 1984, 36:584-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6488678\">[PubMed 6488678]</a></p>\n<p>3. Conrad KA, Byers JM, Finley PR, et al, “Lidocaine Elimination: Effects of Metoprolol and of Propranolol,” <i>Clin Pharmacol Ther</i>, 1983, 33:133-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6822025\">[PubMed 6822025]</a></p>\n<p>4. Graham CF, Turner WM, and Jones JK, “Lidocaine-Propranolol Interactions,” <i>N Engl J Med</i>, 1981, 304:1301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7219480\">[PubMed 7219480]</a></p>\n<p>5. Miners JO, Wing LM, Lillywhite KJ, et al, “Failure of ‘Therapeutic’ Doses of Beta-Adrenoceptor Antagonists to Alter the Disposition of Tolbutamide and Lignocaine,” <i>Br J Clin Pharmacol</i>, 1984, 18:853-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6152176\">[PubMed 6152176]</a></p>\n<p>6. Bowdle TA, Freund PR, Slattery JT, “Propranolol Reduces Bupivacaine Clearance,” <i>Anesthesiology</i>, 1987, 66(1):36-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3800032\">[PubMed 3800032]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5342":"<p><b>Title</b> Bupivacaine / Beta-Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta-Blockers may increase the serum concentration of Bupivacaine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of bupivacaine when used concurrently with beta-blockers.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Levobunolol, Metipranolol, Metoprolol, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Bupivacaine clearance was decreased an average of 35% and its half-life was increased an average of 88% (from 2.6 hrs to 4.9 hrs) when bupivacaine (30-50 mg IV) was administered with propranolol (40 mg every 6 hrs) in a study of 6 healthy volunteers.<sup>1</sup><br><br>The specific mechanism of this interaction is unclear. A similar interaction has been reported with the amide anesthetics lidocaine and mepivacaine.<sup>2,3,4,5,6</sup> Whether this interaction is limited to propranolol or extends to other beta-blockers is also unclear, as data regarding the interaction between lidocaine and other beta-blockers are somewhat mixed.<sup>2,3,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bowdle TA, Freund PR, Slattery JT, “Propranolol Reduces Bupivacaine Clearance,” <i>Anesthesiology</i>, 1987, 66(1):36-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3800032\">[PubMed 3800032]</a></p>\n<p>2. Schneck DW, Luderer JR, Davis D, et al, “Effects of Nadolol and Propranolol on Plasma Lidocaine Clearance,” <i>Clin Pharmacol Ther</i>, 1984, 36:584-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6488678\">[PubMed 6488678]</a></p>\n<p>3. Conrad KA, Byers JM, Finley PR, et al, “Lidocaine Elimination: Effects of Metoprolol and of Propranolol,” <i>Clin Pharmacol Ther</i>, 1983, 33:133-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6822025\">[PubMed 6822025]</a></p>\n<p>4. Graham CF, Turner WM, and Jones JK, “Lidocaine-Propranolol Interactions,” <i>N Engl J Med</i>, 1981, 304:1301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7219480\">[PubMed 7219480]</a></p>\n<p>5. Miners JO, Wing LM, Lillywhite KJ, et al, “Failure of ‘Therapeutic’ Doses of Beta-Adrenoceptor Antagonists to Alter the Disposition of Tolbutamide and Lignocaine,” <i>Br J Clin Pharmacol</i>, 1984, 18:853-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6152176\">[PubMed 6152176]</a></p>\n<p>6. Popescu SM, Nechifor M, Baniceru M, et al, “Effect of Propranolol on Mepivacaine Serum Concentrations in Dental Practice,” <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>, 2008, 105(4):e19-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18329563\">[PubMed 18329563]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5344":"<p><b>Title</b> Pitavastatin / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemfibrozil may enhance the myopathic (rhabdomyolysis) effect of Pitavastatin. Gemfibrozil may increase the serum concentration of Pitavastatin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Pitavastatin labeling states that concurrent use of gemfibrozil and pitavastatin should be avoided. An American Heart Association scientific statement says that this combination may be considered if fenofibrate products are not an option. Consider using micronized fenofibrate, niacin (though pitavastatin dose adjustments may be needed), or some other approach to decrease triglycerides and/or increase HDL when clinically and otherwise appropriate. Regardless of chosen approach, monitor patients for signs and symptoms of rhabdomyolysis during concomitant use of pitavastatin with any other lipid-altering agent.</p> \n<p><b>Discussion</b> Since initial case reports of rhabdomyolysis in patients receiving lovastatin and gemfibrozil,<sup>1</sup> data have accumulated that make it clear that gemfibrozil considerably increases the risk of rhabdomyolysis when combined with HMG-CoA reductase inhibitors. An examination of the FDA Adverse Event Reporting System (AERS) database found that the rate of rhabdomyolysis associated with most of the HMG-CoA reductase inhibitors was increased more than 10-fold when combined with gemfibrozil.<sup>2</sup> Of the 866 cases of rhabdomyolysis in the AERS database, 384 (44%) were associated with concomitant use of gemfibrozil, and more than 50% (479 cases) involved cerivastatin, which is no longer available in the U.S. A separate study of the AERS database found that fenofibrate does not confer the same risk as gemfibrozil when used in combination with the HMG-CoA reductase inhibitors, reporting a risk of rhabdomyolysis at least 15-fold lower with fenofibrate-HMG-CoA reductase inhibitor combinations than with gemfibrozil-HMG-CoA reductase inhibitor combinations.<sup>3</sup> The precise mechanism of this interaction is uncertain, but it does appear to involve both a pharmacokinetic and pharmacodynamic component.<br><br>Concomitant administration of pitavastatin (4 mg daily) and gemfibrozil (600 mg BID) for 7 days increased pitavastatin AUC (45%) and Cmax (31%), compared to pitavastatin monotherapy.<sup>4</sup> The degree of clinical significance of such interaction is uncertain. Given the relatively lower magnitude pharmacokinetic change associated with this interaction, an American Heart Association scientific statement suggests this combination may be considered when use of a fenofibrate product is not a reasonable alternative.<sup>5</sup> Pitavastatin undergoes hepatic uptake via organic anion transporting polypeptide 1B1 (OATP1B1),<sup>6</sup> glucuronidation via uridine 5'-diphosphate (UDP) glucuronosyltransferases (UGT1A3 and UGT2B7), and limited metabolism via CYP2C9 and CYP2C8.<sup>4</sup> Gemfibrozil and its glucuronide inhibit OATP1B1, CYP2C8, and CYP2C9.<sup>6</sup> Possible explanations for the observed pharmacokinetic interaction between these two agents may include, inhibition of hepatic uptake of pitavastatin, inhibition of pitavastatin glucuronidation, inhibition of CYP2C9 and/or CYP2C8-mediated metabolism of pitavastatin, or some combination of these effects. In contrast, fenofibrate does not appear to share gemfibrozil's pharmacokinetic effects, with several studies documenting the lack of a significant pharmacokinetic interaction between fenofibrate and HMG-CoA reductase inhibitors.<sup>6,7,8,9</sup> <br><br>In addition to these pharmacokinetic effects, gemfibrozil has been associated with rhabdomyolysis and other muscle toxicities as monotherapy, raising the possibility of an additional pharmacodynamic interaction. Although the risk of severe muscle toxicity associated with gemfibrozil monotherapy is small (59.6 cases of rhabdomyolysis per million prescriptions), it is considerably greater than that reported with fenofibrate monotherapy (5.5 cases per million prescriptions).<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pierce LR, Wysowski DK, and Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. <i>JAMA</i>. 1990;264(1):71-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2355431\">[PubMed 2355431]</a></p>\n<p>2. Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. <i>Pharmacoepidemiol Drug Saf</i>. 2004;13(7):417-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15269925\">[PubMed 15269925]</a></p>\n<p>3. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. <i>Am J Cardiol</i>. 2005;95(1):120-122. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15619408\">[PubMed 15619408]</a></p>\n<p>4. Livalo (pitavastatin) [prescribing information]. Montgomery, AL: Kowa Pharmaceuticals America, Inc; November 2016.</p>\n<p>5. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(21):e468-e495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27754879\">[PubMed 27754879]</a></p>\n<p>6. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. <i>Clin Pharmacol Ther</i>. 2006;80(6):565-581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17178259\">[PubMed 17178259]</a></p>\n<p>7. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. <i>J Clin Pharmacol</i>. 2004;44(9):1054-1062. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15317833\">[PubMed 15317833]</a></p>\n<p>8. Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. <i>Drug Metab Dispos</i>. 2002;30(11):1280-1287. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12386136\">[PubMed 12386136]</a></p>\n<p>9. Goosen TC, Bauman JN, Davis JA, et al. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. <i>Drug Metab Dispos</i>. 2007;35(8):1315-1324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17470524\">[PubMed 17470524]</a></p>\n<p>10. Alsheikh-Ali AA, Kuvin JT, Karas RH. Risk of adverse events with fibrates. <i>Am J Cardiol</i>. 2004;94(7):935-938. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15464682\">[PubMed 15464682]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5345":"<p><b>Title</b> HYDROmorphone / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROmorphone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Though not specifically contraindicated, the prescribing information for at least one hydromorphone product cautions that hydromorphone is not intended to be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for CNS excitation/depression, hypotension, or hypertension.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The prescribing information for at least one hydromorphone product cautions that hydromorphone is not intended to be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for CNS excitation/depression, hypotension, or hypertension.<sup>1</sup><br><br>The specific mechanism for this potential interaction is unclear. Whether this warning is simply related to the potential for each agent to independently alter CNS activity and/or blood pressure, or whether this relates to concerns over a theoretical potential for excessive serotonin stimulation (as possible with selected other opiates, such as meperidine) is unknown. Of note, one in vitro study did find that hydromorphone was able to interact with the 5-HT<sub>3A</sub> receptor at concentrations estimated to be of potential clinical relevance.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Exalgo (hydromorphone). Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc., 03/2010.</p>\n<p>2. Wittmann M, Schaaf T, Peters I, et al, “The Effects of Fentanyl-like Opioids and Hydromorphone on Human 5-HT<sub>3A</sub> Receptors,” <i>Anesth Analg</i>, 2008, 107(1):107-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18635474\">[PubMed 18635474]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5346":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Methadone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methadone may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, mental status changes, autonomic instability, neuromuscular hyperactivity) if methadone is combined with a monoamine oxidase inhibitor. Canadian methadone labeling lists use with monoamine oxidase inhibitors (or within 14 days of such therapy) as contraindicated.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The US Food and Drug Administration (FDA) issued a drug safety communication warning that opioid analgesics may interact with serotonergic medications and lead to the development of serotonin syndrome.<sup>1</sup> Cases of serotonin syndrome in the FDA Adverse Event Reporting System (FAERS) database were reported most frequently with fentanyl and methadone.<sup>1</sup> A new statement will be added to methadone labeling describing these risks.<sup>1</sup> Canadian methadone labeling lists use with monoamine oxidase inhibitors (or within 14 days of such therapy) as contraindicated.<sup>2</sup><br><br>In addition to cases of serotonin syndrome reported in the FAERS database, cases have been published that implicate methadone as a contributing factor in the development of serotonin syndrome when combined with other serotonin modulators.<sup>3,4,5,6</sup><br><br>Methadone is thought to be a weak serotonin reuptake inhibitor, so the mechanism of these interactions is likely related to additive effects on serotonin.<sup>6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery. Accessed March 24, 2016.</p>\n<p>2. Methadose (methadone) [product monograph]. Saint Laurent, Quebec, Canada: Mallinckrodt Canada ULC; February 2016.</p>\n<p>3. Lee J, Franz L, Goforth HW. Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. <i>Psychosomatics</i>. 2009;50(6):638-639. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19996237\">[PubMed 19996237]</a></p>\n<p>4. Martinez TT, Martinez DN. A case of serotonin syndrome associated with methadone overdose. <i>Proc West Pharmacol Soc</i>. 2008;51:42-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19544673\">[PubMed 19544673]</a></p>\n<p>5. Bush E, Miller C, Friedman I. A case of serotonin syndrome and mutism associated with methadone. <i>J Palliat Med</i>. 2006;9(6):1257-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17187532\">[PubMed 17187532]</a></p>\n<p>6. Hillman AD, Witenko CJ, Sultan SM, Gala G. Serotonin syndrome caused by fentanyl and methadone in a burn injury. <i>Pharmacotherapy</i>. 2015;35(1):112-117. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25615513\">[PubMed 25615513]</a></p>\n<p>7. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. <i>Br J Anaesth</i>. 2005;95(4):434-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16051647\">[PubMed 16051647]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5348":"<p><b>Title</b> Sipuleucel-T / Immunosuppressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Note that concurrent use of immunosuppressants may interfere with the clinical actions of sipuleucel. Consider avoiding such combinations when clinically appropriate. If such a combination is used, monitor the patient closely for clinical response.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine<br><b>Exception</b> Cytarabine (Liposomal)</p>\n</div> \n<p><b>Discussion</b> Though specific data regarding this potential interaction are not available, based on the immune-stimulating activity of sipuleucel-T, it is possible that concurrent use of drugs that suppress the immune the system may interfere with the clinical activity of sipuleucel-T.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Provenge (sipuleucel-T). Seattle, WA: Dendreon Corporation, April 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5349":"<p><b>Title</b> Propofol / Midazolam</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Midazolam may increase the serum concentration of Propofol. Propofol may increase the serum concentration of Midazolam. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Increase monitoring of clinical response to both midazolam and propofol when these agents are used together.</p> \n<p><b>Discussion</b> Average midazolam plasma concentrations were 27% higher with concurrent propofol (average blood concentration 1.2 mcg/mL) in a study of 8 healthy volunteers.<sup>1</sup> Both the midazolam elimination clearance and distribution clearance were decreased with concurrent propofol (by 21% and 24%, repectively), and the midazolam central volume of distribution was also significantly decreased. Similarly, midazolam clearance was an average of 37% lower and the midazolam half-life was 61% higher with concurrent propofol in a study of 24 patients.<sup>2</sup><br><br>The likely mechanism of this apparent interaction is propofol-mediated inhibition of midazolam metabolism via CYP3A4. Both in vivo and in vitro studies have found decreased 1'-hydroxymidazolam (formed by CYP3A metabolism) concentrations with concurrent propofol, with additional in vitro evidence that propofol is a competitive inhibitor of this process.<sup>2</sup><br><br>Also of note, propofol blood concentrations were an average of 25% higher with concurrent midazolam in a study of 8 healthy volunteers.<sup>3</sup> The specific mechanism(s) and clinical significance of this possible interaction are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lichtenbelt BJ, Olofsen E, Dahan A, et al, “Propofol Reduces the Distribution and Clearance of Midazolam,” <i>Anesth Analg</i>, 2010, Apr 30 [Epub ahead of print]. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20435936\">[PubMed 20435936]</a></p>\n<p>2. Hamaoka N, Oda Y, Hase I, et al, “Propofol Decreases the Clearance of Midazolam by Inhibiting CYP3A4: An In Vivo and In Vitro Study,” <i>Clin Pharmacol Ther</i>, 1999, 66(2):110-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10460064\">[PubMed 10460064]</a></p>\n<p>3. Vuyk J, Lichtenbelt BJ, Olofsen E, et al, “Mixed-effects Modeling of the Influence of Midazolam on Propofol Pharmacokinetics,” <i>Anesth Analg</i>, 2009, 108(5):1522-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19372331\">[PubMed 19372331]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5350":"<p><b>Title</b> Midazolam / Protease Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Severity of interaction likely to be notably greater with oral midazolam.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of Midazolam. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concurrent use of oral midazolam is contraindicated with all protease inhibitors. Regarding intravenous midazolam, concurrent use with fosamprenavir is contraindicated; use with any other protease inhibitors should only be done with caution and in a setting equipped to appropriately monitor for and treat any excessive response to midazolam. Reduced doses of intravenous midazolam should be considered, particularly if multiple doses may be used.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Several studies in healthy volunteers and HIV-infected patients have reported substantial increases (5- to 28-fold) in midazolam AUC and/or 65-96% reductions in midazolam oral clearance when oral midazolam was given with saquinavir, ritonavir, or ritonavir-boosted doses of lopinavir, saquinavir, or tipranavir.<sup>1,2,3,4,5,6,7,8</sup> Studies of intravenous midazolam have also reported clinically meaningful increases in midazolam AUC (1.5- to 5.1-fold) and/or decreased midazolam clearance (76-77%) with concurrent saquinavir, lopinavir/ritonavir, or tipranavir/ritonavir.<sup>5,6,7,8</sup><br><br>Of note, one study found that ritonavir appears to have a particularly substantial interaction with midazolam (especially oral midazolam), with clinically significant inhibition of midazolam clearance with ritonavir doses as low as 20 mg (65% decrease in midazolam clearance) and greater than an 80% decrease in midazolam clearance with a single 100 mg ritonavir dose.<sup>4</sup> Also, the interaction involving ritonavir-boosted tipranavir appears to diminish in magnitude (though it is still considerable) between initiation of tipranavir/ritonavir and the attainment of steady-state. Following administration of a single dose of oral midazolam with tipranavir/ritonavir (500 mg/200 mg BID), midazolam AUC was increased an average of 27-fold when given on day 2 of tipranavir/ritonavir versus an increase in midazolam AUC of only 10.3-fold when oral midazolam was given on day 12 of tipranavir/ritonavir (n=23 healthy volunteers). Similarly, the midazolam AUC following administration of single IV midazolam doses was increased an average of 5.1- and 2.9-fold when given on day 3 or day 13, respectively, of tipranavir/ritonavir.<sup>7</sup><br><br>Severe prolonged sedation was more common among those receiving a protease inhibitor-containing antiretroviral regimen (n=51) than among HIV-positive individuals who were not taking antiretrovirals (n=190) (9.8% vs. 1.6%, respectively) in a retrospective study of individuals who received midazolam sedation for bronchoscopy.<sup>9</sup> Protease inhibitors specifically associated with prolonged sedation were atazanavir/ritonavir and lopinavir/ritonavir.<br><br>The mechanism of this interaction appears to be inhibition of the CYP3A-mediated metabolism of midazolam by individual protease inhibitors. The interaction with oral midazolam is likely of greater magnitude due to inhibition of CYP3A in both the intestine and liver, and the resultant decrease in first pass metabolism of midazolam.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Greenblatt DJ, Peters DE, Oleson LE, et al, “Inhibition of Oral Midazolam Clearance by Boosting Doses of Ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an Experimental Catalytic Mimic of Glutathione Oxidase,” <i>Br J Clin Pharmacol</i>, 2009, 68(6):920-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20002087\">[PubMed 20002087]</a></p>\n<p>2. Schmitt C, Hofmann C, Riek M, et al, “Effect of Saquinavir-Ritonavir on Cytochrome P450 3A4 Activity in Healthy Volunteers Using Midazolam as a Probe,” <i>Pharmacotherapy</i>, 2009, 29(10):1175-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19792991\">[PubMed 19792991]</a></p>\n<p>3. Knox TA, Oleson L, von Moltke LL, et al, “Ritonavir Greatly Impairs CYP3A Activity in HIV Infection with Chronic Viral Hepatitis,” <i>J Acquir Immune Defic Syndr</i>, 2008, 49(4):358-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19186349\">[PubMed 19186349]</a></p>\n<p>4. Mathias AA, West S, Hui J, et al, “Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure,” <i>Clin Pharmacol Ther</i>, 2009, 85(1):64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18815591\">[PubMed 18815591]</a></p>\n<p>5. Yeh RF, Gaver VE, Patterson KB, et al, “Lopinavir/Ritonavir Induces the Hepatic Activity of Cytochrome P450 Enzymes CYP2C9, CYP2C19, and CYP1A2 but Inhibits the Hepatic and Intestinal Activity of CYP3A as Measured by a Phenotyping Drug Cocktail in Healthy Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2006, 42(1):52-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16639344\">[PubMed 16639344]</a></p>\n<p>6. Palkama VJ, Ahonen J, Neuvonen PJ, et al, “Effect of Saquinavir on the Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Midazolam,” <i>Clin Pharmacol Ther</i>, 1999, 66(1):33-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10430107\">[PubMed 10430107]</a></p>\n<p>7. Dumond JB, Vourvahis M, Rezk NL, et al, “A Phenotype-Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir,” <i>Clin Pharmacol Ther</i>, 2010, Feb 10. [Epub ahead of print] <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20147896\">[PubMed 20147896]</a></p>\n<p>8. Wyen C, Fuhr U, Frank D, et al, “Effect of an Antiretroviral Regimen Containing Ritonavir Boosted Lopinavir on Intestinal and Hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-Infected Patients,” <i>Clin Pharmacol Ther</i>, 2008, 84(1):75-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18183034\">[PubMed 18183034]</a></p>\n<p>9. Hsu AJ, Carson KA, Yung R, et al, “Severe Prolonged Sedation Associated with Coadministration of Protease Inhibitors and Intravenous Midazolam During Bronchoscopy,” <i>Pharmacotherapy</i>, 2012, 32(6):538-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22488554\">[PubMed 22488554]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5353":"<p><b>Title</b> ALPRAZolam / Indinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Indinavir may increase the serum concentration of ALPRAZolam. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of alprazolam with indinavir is contraindicated.</p> \n<p><b>Discussion</b> Concurrent use of alprazolam with indinavir is contraindicated,<sup>1</sup> and although specific data about this likely interaction are not available, data regarding the interaction of alprazolam with other protease inhibitors are available.<br><br>Alprazolam clearance was reduced by an average of 59% when alprazolam (1 mg) was given with ritonavir (200 mg twice daily x 4 doses), and the average alprazolam elimination half-life more than doubled (30 hrs vs. 13 hrs).<sup>2</sup> An unpublished in vitro study reportedly also found that ritonavir strongly inhibited alprazolam metabolism.<sup>3</sup><br><br>In contrast, alprazolam AUC was not significantly changed when a single dose of alprazolam was given after 10 days of ritonavir (500 mg twice daily) pre-treatment in a study of 12 healthy volunteers.<sup>4</sup> The authors of a review/commentary hypothesized that this apparently discrepant finding is due to ritonavir's ability to both inhibit and induce certain drug metabolizing enzymes, and in this case, the ritonavir-mediated inhibition of alprazolam metabolism was offset by ritonavir-mediated induction of CYP3A.<sup>3</sup><br><br>Available data suggest this interaction may be dependent on which protease inhibitor is involved, with ritonavir and other “inducing” protease inhibitors (e.g., tipranavir) more likely to be involved in significant interactions early in therapy (i.e., prior to full induction) and with other protease inhibitors likely displaying a more consistent risk of interactions. Of note, the prescribing information for indinavir lists concurrent use of alprazolam as a contraindication,<sup>1</sup> the prescribing information for both fosamprenavir and saquinavir recommend caution with use of concurrent alprazolam,<sup>5,6</sup> and the prescribing information for other protease inhibitors do not comment specifically on alprazolam.<sup>7,8,9,10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Crixivan (indinavir). Whitehouse Station, NJ: Merck &amp; Co., Inc., January 2010.</p>\n<p>2. Greenblatt DJ, von Moltke LL, Harmatz JS, et al, “Alprazolam-Ritonavir Interaction: Implications for Product Labeling,” <i>Clin Pharmacol Ther</i>, 2000, 67(4):335-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10801241\">[PubMed 10801241]</a></p>\n<p>3. Greenblatt DJ, von Moltke LL, Daily JP, et al, “Extensive Impairment of Triazolam and Alprazolam Clearance by Short-Term Low-Dose Ritonavir: The Clinical Dilemma of Concurrent Inhibition and Induction,” <i>J Clin Psychopharmacol</i>, 1999, 19(4):293-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10440454\">[PubMed 10440454]</a></p>\n<p>4. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 04/2010.</p>\n<p>5. Prescribing information. Lexiva (fosamprenavir). Princeton, NJ: Bristol-Myers Squibb Company, September 2009.</p>\n<p>6. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., March 2010.</p>\n<p>7. Prescribing information. Reyataz (atazanavir). Princeton, NJ: Bristol-Myers Squibb Company, 04/2010.</p>\n<p>8. Prescribing information. Prezista (darunavir). Raritan, NJ: Tibotec Therapeutics, Division of Centocor Ortho Biotech Products, L.P., 04/2010.</p>\n<p>9. Prescribing information. Kaletra (lopinavir and ritonavir). North Chicago, IL: Abbott Laboratories, 04/2010.</p>\n<p>10. Prescribing information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 4/2010.</p>\n<p>11. Prescribing information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, Inc., 04/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5354":"<p><b>Title</b> Clorazepate / Fosamprenavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosamprenavir may increase the serum concentration of Clorazepate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs of excessive response to clorazepate if this combination is used. Decreased clorazepate doses may be necessary.</p> \n<p><b>Discussion</b> Though specific interaction data and/or case reports regarding this possible interaction are not available, the fosamprenavir prescribing information recommends using caution when using fosamprenavir and clorazepate together.<sup>1</sup> Use of this combination may result in increased sedative effects and/or impaired motor function; decreased clorazepate doses may be needed.<br><br>Fosamprenavir is an inhibitor of CYP3A4 and p-glycoprotein, suggesting that inhibition of clorazepate metabolism/transport would be the likely mechanism for any observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lexiva (fosamprenavir). Princeton, NJ: Bristol-Myers Squibb Company, September 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5355":"<p><b>Title</b> DiazePAM / Fosamprenavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosamprenavir may increase the serum concentration of DiazePAM. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs of excessive response to diazepam if this combination is used. Decreased diazepam doses may be necessary.</p> \n<p><b>Discussion</b> Though specific interaction data and/or case reports regarding this possible interaction are not available, the fosamprenavir prescribing information recommends using caution when using fosamprenavir and diazepam together.<sup>1</sup> Use of this combination may result in increased sedative effects and/or impaired motor function; decreased diazepam doses may be needed.<br><br>Fosamprenavir is an inhibitor of CYP3A4 and p-glycoprotein, suggesting that inhibition of diazepam metabolism/transport would be the likely mechanism for any observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lexiva (fosamprenavir). Princeton, NJ: Bristol-Myers Squibb Company, September 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5356":"<p><b>Title</b> Flurazepam / Fosamprenavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosamprenavir may increase the serum concentration of Flurazepam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs of excessive response to flurazepam if this combination is used. Decreased flurazepam doses may be necessary.</p> \n<p><b>Discussion</b> Though specific interaction data and/or case reports regarding this possible interaction are not available, the fosamprenavir prescribing information recommends using caution when using fosamprenavir and flurazepam together.<sup>1</sup> Use of this combination may result in increased sedative effects and/or impaired motor function; decreased flurazepam doses may be needed.<br><br>Fosamprenavir is an inhibitor of CYP3A4 and p-glycoprotein, suggesting that inhibition of flurazepam metabolism/transport would be the likely mechanism for any observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lexiva (fosamprenavir). Princeton, NJ: Bristol-Myers Squibb Company, September 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5357":"<p><b>Title</b> Clorazepate / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Saquinavir may increase the serum concentration of Clorazepate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs of excessive response to clorazepate if this combination is used. Decreased clorazepate doses may be necessary.</p> \n<p><b>Discussion</b> Though specific interaction data and/or case reports regarding this possible interaction are not available, the saquinavir prescribing information recommends using caution when using saquinavir and clorazepate together.<sup>1</sup> Use of this combination may result in increased sedative effects and/or impaired motor function; decreased clorazepate doses may be needed.<br><br>Saquinavir is an inhibitor of CYP3A4 and p-glycoprotein, suggesting that inhibition of clorazepate metabolism/transport would be the likely mechanism for any observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., March 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5358":"<p><b>Title</b> DiazePAM / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Saquinavir may increase the serum concentration of DiazePAM. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs of excessive response to diazepam if this combination is used. Decreased diazepam doses may be necessary.</p> \n<p><b>Discussion</b> Though specific interaction data and/or case reports regarding this possible interaction are not available, the saquinavir prescribing information recommends using caution when using saquinavir and diazepam together.<sup>1</sup> Use of this combination may result in increased sedative effects and/or impaired motor function; decreased diazepam doses may be needed.<br><br>Saquinavir is an inhibitor of CYP3A4 and p-glycoprotein, suggesting that inhibition of diazepam metabolism/transport would be the likely mechanism for any observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., March 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5359":"<p><b>Title</b> Flurazepam / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Saquinavir may increase the serum concentration of Flurazepam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs of excessive response to flurazepam if this combination is used. Decreased flurazepam doses may be necessary.</p> \n<p><b>Discussion</b> Though specific interaction data and/or case reports regarding this possible interaction are not available, the saquinavir prescribing information recommends using caution when using saquinavir and flurazepam together.<sup>1</sup> Use of this combination may result in increased sedative effects and/or impaired motor function; decreased flurazepam doses may be needed.<br><br>Saquinavir is an inhibitor of CYP3A4 and p-glycoprotein, suggesting that inhibition of flurazepam metabolism/transport would be the likely mechanism for any observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., March 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5360":"<p><b>Title</b> Clorazepate / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Clorazepate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs of excessive response to clorazepate if this combination is used. Decreased clorazepate doses may be necessary.</p> \n<p><b>Discussion</b> Though specific interaction data and/or case reports regarding this possible interaction are not available, the ritonavir prescribing information recommends using caution when using ritonavir and clorazepate together.<sup>1</sup> Use of this combination may result in increased sedative effects and/or impaired motor function; decreased clorazepate doses may be needed.<br><br>Ritonavir is an inhibitor of CYP3A4 and p-glycoprotein, suggesting that inhibition of clorazepate metabolism/transport would be the likely mechanism for any observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 04/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5361":"<p><b>Title</b> DiazePAM / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of DiazePAM. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs of excessive response to diazepam if this combination is used. Decreased diazepam doses may be necessary.</p> \n<p><b>Discussion</b> Though specific interaction data and/or case reports regarding this possible interaction are not available, the ritonavir prescribing information recommends using caution when using ritonavir and diazepam together.<sup>1</sup> Use of this combination may result in increased sedative effects and/or impaired motor function; decreased diazepam doses may be needed.<br><br>Ritonavir is an inhibitor of CYP3A4 and p-glycoprotein, suggesting that inhibition of diazepam metabolism/transport would be the likely mechanism for any observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 04/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5362":"<p><b>Title</b> Estazolam / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Estazolam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs of excessive response to estazolam if this combination is used. Decreased estazolam doses may be necessary.</p> \n<p><b>Discussion</b> Though specific interaction data and/or case reports regarding this possible interaction are not available, the ritonavir prescribing information recommends using caution when using ritonavir and estazolam together.<sup>1</sup> Use of this combination may result in increased sedative effects and/or impaired motor function; decreased estazolam doses may be needed.<br><br>Ritonavir is an inhibitor of CYP3A4 and p-glycoprotein, suggesting that inhibition of estazolam metabolism/transport would be the likely mechanism for any observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 04/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5363":"<p><b>Title</b> Flurazepam / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Flurazepam. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for signs of excessive response to flurazepam if this combination is used. Decreased flurazepam doses may be necessary.</p> \n<p><b>Discussion</b> Though specific interaction data and/or case reports regarding this possible interaction are not available, the ritonavir prescribing information recommends using caution when using ritonavir and flurazepam together.<sup>1</sup> Use of this combination may result in increased sedative effects and/or impaired motor function; decreased flurazepam doses may be needed.<br><br>Ritonavir is an inhibitor of CYP3A4 and p-glycoprotein, suggesting that inhibition of flurazepam metabolism/transport would be the likely mechanism for any observed interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 04/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5364":"<p><b>Title</b> Alfuzosin / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Protease Inhibitors may increase the serum concentration of Alfuzosin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of alfuzosin with any protease inhibitor is contraindicated.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Concurrent use of alfuzosin with any strong CYP3A4 inhibitor (which includes several protease inhibitors) is contraindicated according to alfuzosin prescribing information,<sup>1</sup> and this contraindication has been expanded to include all protease inhibitors.<br><br>Though specific data with protease inhibitors are not available, data with other CYP3A inhibitors provide relevant information about this predicted interaction. Alfuzosin AUC and maximum plasma concentration (Cmax) were increased 3.2- and 2.3-fold, respectively, following administration (single 10mg alfuzosin dose) with the strong CYP3A4 inhibitor ketoconazole (400mg daily).<sup>1</sup> A study with diltiazem (240mg/day), a more moderate CYP3A4 inhibitor, showed a less substantial interaction, with an 1.3-fold increase in alfuzosin AUC and a 1.5-fold increase in alfuzosin Cmax.<sup>1</sup><br><br>As alfuzosin is metabolized by CYP3A4, the presumed mechanism of this interaction is decreased alfuzosin metabolism by strong CYP3A4 inhibitors such as ketoconazole, leading to increased alfuzosin concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Uroxatral (alfuzosin). Bidgewater, NJ: Sanofi-Aventis U.S. LLC, April 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5365":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Everolimus</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Everolimus may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Note that an increased risk of angioedema has been reported with this combination. Caution patients regarding this increased risk, and urge them to immediately report any signs or symptoms suggestive of possible angioedema.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The prescribing information for both sirolimus and everolimus (target of rapamycin [mTOR] inhibitors) cautions that angioedema has been reported with their use and that concurrent use with other drugs associated with development of angioedema, such as the angiotensin-converting enzyme (ACE) inhibitors, may increase the risk.<sup>1,2</sup><br><br>In one retrospective study of 137 patients receiving an mTOR inhibitor and an ACE inhibitor, 6.6% developed angioedema (3.8 per 100 treatment-years) as compared with only 1.2% (0.5/100 treatment-years) of those receiving an mTOR inhibitor without an ACE inhibitor (n=172, including 119 on an angiotensin receptor blocker) and 2.1% (0.8/100 treatment-years) of those receiving mycophenolate plus an ACE inhibitor (n=462).<sup>3</sup> These figures also exceed the general rate of angioedema associated with ACE inhibitor use (independent of immunosuppressant use) in a recent study of a US Veterans Affairs Health Care System population, in which 0.2% of patients started on an ACE inhibitor experienced angioedema (0.197/100 patient-years).<sup>4</sup> A published case report also describes a 58-year-old woman receiving ramipril who developed angioedema 1 month after initiating everolimus, but who later tolerated everolimus alone without angioedema.<sup>5</sup><br><br>The specific mechanism by which mTOR inhibitors increase the risk of angioedema is unclear. ACE inhibitors may contribute to the development of angioedema through their ability to inhibit the metabolism of specific vasoactive kinins (eg, bradykinin).</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zortress</i> (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2010.</p>\n<p>2. <i>Rapamune</i> (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; April 2010.</p>\n<p>3. Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. <i>Clin J Am Soc Nephrol</i>. 2010;5(4):703-708. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20093343\">[PubMed 20093343]</a></p>\n<p>4. Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. <i>Hypertension</i>. 2008;51(6):1624-1630. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18413488\">[PubMed 18413488]</a></p>\n<p>5. Rothermundt C, Gillessen S. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor. <i>J Clin Oncol</i>. 2013;31(5):e57-e58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23295800\">[PubMed 23295800]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5366":"<p><b>Title</b> Lycopene / Beta-Carotene</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Beta-Carotene may increase the serum concentration of Lycopene. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 10 healthy men, coadministration of all-trans beta-carotene (60 mg orally, Henkel Corp, LaGrange, IL) with all-trans lycopene (60 mg orally, Makhteshim-Agan of North America, Inc., New York, NY) increased the 24-hour AUC (a measure of drug exposure) of lycopene by greater than fourfold.<sup>1</sup> AUC of beta carotene was unaffected by coadministration. In a later study of 12 healthy men, coadministration of lycopene (15 mg orally from tomato oleoresin concentrate) with beta carotene (15 mg orally from a palm fruit preparation) similarly had no significant impact on 10 hour AUC of beta carotene, as measured in the plasma triacylglycerol-rich lipoprotein fraction.<sup>2,3</sup><br><br>The mechanism of this apparent interaction is unknown. In the cited studies, the limited pharmacokinetic analysis precludes any mechanistic inference.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Johnson EJ, Qin J, Krinsky NI, et al, “Ingestion by Men of a Combined Dose of Beta-Carotene and Lycopene Does Not Affect the Absorption of Beta-Carotene but Improves that of Lycopene,” <i>J Nutr</i>, 1997, 127(9):1833-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9278568\">[PubMed 9278568]</a></p>\n<p>2. van den Berg H and van Vliet T, “Effect of Simultaneous, Single Oral Doses of Beta-Carotene with Lutein or Lycopene on the Beta-Carotene and Retinyl Ester Responses in the Triacylglycerol-Rich Lipoprotein Fraction of Men,” <i>Am J Clin Nutr</i>, 1998, 68(1):82-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9665100\">[PubMed 9665100]</a></p>\n<p>3. van den Berg H, “Effect of Lutein on Beta-Carotene Absorption and Cleavage,” <i>Int J Vitam Nutr Res</i>, 1998, 68(6):360-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9857262\">[PubMed 9857262]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5367":"<p><b>Title</b> Lutein / Beta-Carotene</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Beta-Carotene may decrease the serum concentration of Lutein. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 8 healthy volunteers, coadministration of all-trans beta-carotene (0.5 micromol/kg orally, General Nutrition Corporation, Pittsburgh, PA) with all-trans lutein (0.5 micromol/kg orally, extracted from lutein-rich marigold extract) decreased average AUC (a measure of drug exposure) of lutein by approximately 40% (range -79% - +15%).<sup>1</sup> The AUC of beta carotene was not significantly increased or decreased by coadministration. In a later study of 12 healthy men, coadministration of lutein (15 mg orally prepared from marigold flower extract) with beta carotene (15 mg orally from a palm fruit preparation) decreased the triglyceride-adjusted 10 hour AUC of beta carotene by 34%, as measured in the plasma triacylglycerol-rich lipoprotein fraction.<sup>2,3</sup> In a follow-up study, roughly the same magnitude of decrease in beta carotene AUC was seen when the compounds were given in a 1:2 (beta carotene:lutein) ratio, but no change in beta carotene AUC was apparent when the compounds were given in a 2:1 ratio.<br><br>The mechanism of this apparent interaction is unknown. In both cited studies, the limited pharmacokinetic analysis precludes any mechanistic inference. Additionally, there appears to be high intersubject variability in the nature and magnitude of the apparent interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kostic D, White WS and Olson JA, “Intestinal Absorption, Serum Clearance, and Interactions between Lutein and Beta-Carotene when Administered to Human Adults in Separate or Combined Oral Doses,” <i>Am J Clin Nutr</i>, 1995, 62(3):604-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7661123\">[PubMed 7661123]</a></p>\n<p>2. van den Berg H and van Vliet T, “Effect of Simultaneous, Single Oral Doses of Beta-Carotene with Lutein or Lycopene on the Beta-Carotene and Retinyl Ester Responses in the Triacylglycerol-Rich Lipoprotein Fraction of Men,” <i>Am J Clin Nutr</i>, 1998, 68(1):82-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9665100\">[PubMed 9665100]</a></p>\n<p>3. van den Berg H, “Effect of Lutein on Beta-Carotene Absorption and Cleavage,” <i>Int J Vitam Nutr Res</i>, 1998, 68(6):360-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9857262\">[PubMed 9857262]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5368":"<p><b>Title</b> ChlordiazePOXIDE / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Disulfiram may increase the serum concentration of ChlordiazePOXIDE. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of chlordiazepoxide if disulfiram is initiated, or the dose is increased. Lorazepam and oxazepam may be less likely to interact.</p> \n<p><b>Discussion</b> Disulfiram (500 mg/day for 2 weeks) reduced the clearance of chlordiazepoxide (50 mg IV x1) and diazepam (0.143 mg/kg orally x1) by 54% and 41%, respectively, and was associated with decreased concentrations of each drug's active N-desmethyl metabolites.<sup>1</sup> Conversely, the clearance of oxazepam (0.429 mg/kg orally x1), which is directly conjugated and does not undergo N-desmethylation, was unaffected. Alprazolam (metabolized via CYP3A) and lorazepam (directly conjugated) similarly appear to be unaffected by disulfiram.<sup>2,3</sup> A single report describes presumed temazepam toxicity which developed a few days after starting the agent in a patient who had been receiving disulfiram (200 mg/day).<sup>4</sup> The symptoms ceased upon discontinuation of both agents, and thus no specific cause/effect relationship can be established.<br><br>The specific mechanism of this interaction is unclear, but the interaction is likely due to inhibition of some metabolism pathway(s) of certain benzodiazepines, and thus is not expected to affect all agents similarly. Disulfiram is an inhibitor of CYP2E1 but does not appear to be a potent inhibitor of other major cytochrome P450 enzymes.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. MacLeod SM, Sellers EM, Giles HG, et al, “Interaction of Disulfiram With Benzodiazepines,” <i>Clin Pharmacol Ther</i>, 1978, 24:583-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29739\">[PubMed 29739]</a></p>\n<p>2. Diquet B, Gujadhur L, Lamiable D, et al, “Lack of Interaction Between Disulfiram and Alprazolam in Alcoholic Patients,” <i>Eur J Clin Pharmacol</i>, 1990, 38:157-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2338112\">[PubMed 2338112]</a></p>\n<p>3. Sellers EM, Giles HG, Greenblatt DJ, et al, “Differential Effects of Benzodiazepine Disposition by Disulfiram and Ethanol,” <i>Arzneimittelforschung</i>, 1980, 30(5a):882-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6106489\">[PubMed 6106489]</a></p>\n<p>4. Hardman M, Biniwale A, Clarke CE, “Temazepam Toxicity Precipitated by Disulfiram,” <i>Lancet</i>, 1994, 334:1231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7934566\">[PubMed 7934566]</a></p>\n<p>5. Kharasch ED, Hankins DC, Jubert C, et al, “Lack of Single-Dose Disulfiram Effects on Cytochrome P-450 2C9, 2C19, 2D6, and 3A4 Activities: Evidence for Specificity Toward P-450 2E1,” <i>Drug Metab Dispos</i>, 1999, 27(6):717-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348802\">[PubMed 10348802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5369":"<p><b>Title</b> DiazePAM / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Disulfiram may increase the serum concentration of DiazePAM. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of diazepam if disulfiram is initiated, or the dose is increased. Lorazepam and oxazepam may be less likely to interact.</p> \n<p><b>Discussion</b> Disulfiram (500 mg/day for 2 weeks) reduced the clearance of chlordiazepoxide (50 mg IV x1) and diazepam (0.143 mg/kg orally x1) by 54% and 41%, respectively, and was associated with decreased concentrations of each drug's active N-desmethyl metabolites.<sup>1</sup> Conversely, the clearance of oxazepam (0.429 mg/kg orally x1), which is directly conjugated and does not undergo N-desmethylation, was unaffected. Alprazolam (metabolized via CYP3A) and lorazepam (directly conjugated) similarly appear to be unaffected by disulfiram.<sup>2,3</sup> A single report describes presumed temazepam toxicity which developed a few days after starting the agent in a patient who had been receiving disulfiram (200 mg/day).<sup>4</sup> The symptoms ceased upon discontinuation of both agents, and thus no specific cause/effect relationship can be established.<br><br>The specific mechanism of this interaction is unclear, but the interaction is likely due to inhibition of some metabolic pathway(s) of certain benzodiazepines, and thus is not expected to affect all agents similarly. Disulfiram is an inhibitor of CYP2E1 but does not appear to be a potent inhibitor of other major cytochrome P450 enzymes.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. MacLeod SM, Sellers EM, Giles HG, et al, “Interaction of Disulfiram With Benzodiazepines,” <i>Clin Pharmacol Ther</i>, 1978, 24:583-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29739\">[PubMed 29739]</a></p>\n<p>2. Diquet B, Gujadhur L, Lamiable D, et al, “Lack of Interaction Between Disulfiram and Alprazolam in Alcoholic Patients,” <i>Eur J Clin Pharmacol</i>, 1990, 38:157-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2338112\">[PubMed 2338112]</a></p>\n<p>3. Sellers EM, Giles HG, Greenblatt DJ, et al, “Differential Effects of Benzodiazepine Disposition by Disulfiram and Ethanol,” <i>Arzneimittelforschung</i>, 1980, 30(5a):882-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6106489\">[PubMed 6106489]</a></p>\n<p>4. Hardman M, Biniwale A, Clarke CE, “Temazepam Toxicity Precipitated by Disulfiram,” <i>Lancet</i>, 1994, 334:1231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7934566\">[PubMed 7934566]</a></p>\n<p>5. Kharasch ED, Hankins DC, Jubert C, et al, “Lack of Single-Dose Disulfiram Effects on Cytochrome P-450 2C9, 2C19, 2D6, and 3A4 Activities: Evidence for Specificity Toward P-450 2E1,” <i>Drug Metab Dispos</i>, 1999, 27(6):717-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348802\">[PubMed 10348802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5370":"<p><b>Title</b> Temazepam / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Disulfiram may increase the serum concentration of Temazepam. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for toxic effects of temazepam if disulfiram is initiated, or the dose is increased. Lorazepam and oxazepam may be less likely to interact.</p> \n<p><b>Discussion</b> A single report describes presumed temazepam toxicity which developed a few days after starting the agent in a patient who had been receiving disulfiram (200 mg/day).<sup>1</sup> The symptoms ceased upon discontinuation of both agents, and thus no specific cause/effect relationship can be established.<br><br>Of note, studies with other benzodiazepines have yielded mixed results. Disulfiram (500 mg/day for 2 weeks) reduced the clearance of chlordiazepoxide (50 mg IV x1) and diazepam (0.143 mg/kg orally x1) by 54% and 41%, respectively, and was associated with decreased concentrations of each drug's active N-desmethyl metabolites.<sup>2</sup> Conversely, the clearance of oxazepam (0.429 mg/kg orally x1), which is directly conjugated and does not undergo N-desmethylation, was unaffected. Alprazolam (metabolized via CYP3A) and lorazepam (directly conjugated) similarly appear to be unaffected by disulfiram.<sup>3,4</sup><br><br>The specific mechanism of this interaction is unclear, but the interaction is likely due to inhibition of some metabolism pathway(s) of certain benzodiazepines, and thus is not expected to affect all agents similarly. Disulfiram is an inhibitor of CYP2E1 but does not appear to be a potent inhibitor of other major cytochrome P450 enzymes.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hardman M, Biniwale A, Clarke CE, “Temazepam Toxicity Precipitated by Disulfiram,” <i>Lancet</i>, 1994, 334:1231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7934566\">[PubMed 7934566]</a></p>\n<p>2. MacLeod SM, Sellers EM, Giles HG, et al, “Interaction of Disulfiram With Benzodiazepines,” <i>Clin Pharmacol Ther</i>, 1978, 24:583-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29739\">[PubMed 29739]</a></p>\n<p>3. Diquet B, Gujadhur L, Lamiable D, et al, “Lack of Interaction Between Disulfiram and Alprazolam in Alcoholic Patients,” <i>Eur J Clin Pharmacol</i>, 1990, 38:157-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2338112\">[PubMed 2338112]</a></p>\n<p>4. Sellers EM, Giles HG, Greenblatt DJ, et al, “Differential Effects of Benzodiazepine Disposition by Disulfiram and Ethanol,” <i>Arzneimittelforschung</i>, 1980, 30(5a):882-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6106489\">[PubMed 6106489]</a></p>\n<p>5. Kharasch ED, Hankins DC, Jubert C, et al, “Lack of Single-Dose Disulfiram Effects on Cytochrome P-450 2C9, 2C19, 2D6, and 3A4 Activities: Evidence for Specificity Toward P-450 2E1,” <i>Drug Metab Dispos</i>, 1999, 27(6):717-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10348802\">[PubMed 10348802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5371":"<p><b>Title</b> Loop Diuretics / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased diuretic effects and/or increased adverse effects of loop diuretics with initiation/dose increase of probenecid. Conversely, monitor for increased diuretic effects with dose decrease/discontinuation of probenecid. Bumetanide prescribing information recommends against concomitant use with probenecid.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> In 9 healthy subjects receiving furosemide (80 mg PO single dose) with or without probenecid pretreatment (1 g single dose), probenecid pretreatment decreased the renal clearance of furosemide and its acyl glucuronide approximately 35% and 30% respectively and increased the AUC of both parent drug and metabolite approximately 3-fold each.<sup>1</sup> In 6 healthy subjects receiving placebo or probenecid (500 mg TID) prior to bumetanide (2 mg PO single dose), the extent of natriuresis was significantly decreased with probenecid pretreatment.<sup>2</sup> <br><br>Probenecid competes with loop diuretics for active tubular secretion and may diminish their diuretic effects and increase their serum concentrations. Bumetanide prescribing information specifically recommends against concomitant use with probenecid.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vree TB, Van Den Biggelaar-Martea M, Verwey-Van Wissen C, “Probenecid Inhibits the Renal Clearance of Frusemide and Its Acyl Glucuronide,” <i>Br J Clin Pharmacol</i>, 1995, 39:692-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7654491\">[PubMed 7654491]</a></p>\n<p>2. Velasquez MT, Wan SH, Barr JW, et al, “Effect of Probenecid on the Natriuresis and Renin Release Induced by Bumetanide in Man,” <i>J Clin Pharmacol</i>, 1981, 21:657-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7040495\">[PubMed 7040495]</a></p>\n<p>3. Prescribing information. Bumetanide. Bedford, OH: Bedford Laboratories, February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5373":"<p><b>Title</b> Mitotane / Spironolactone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Spironolactone may diminish the therapeutic effect of Mitotane. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeutic failure of the mitotane. It is unclear if the specific aldosterone antagonist eplerenone would interact in the same manner. Monitor for decreased therapeutic effects of mitotane during concomitant use of spironolactone, or increased toxic effects if spironolactone is discontinued/dose decreased. Use caution.</p> \n<p><b>Discussion</b> A case report describes a patient with bilateral adrenal hyperplasia in whom the therapeutic effects of mitotane were apparently blocked by concurrent treatment with anti-aldosterone agent spironolactone.<sup>1</sup> The spironolactone was discontinued on the basis of animal study data suggesting that it blocks mitotane's pharmacologic action on adrenocortical tissue,<sup>1</sup> with subsequent development of mitotane toxicity. The patient was unable to tolerate mitotane in the absence of spironolactone. The mechanism of this interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wortsman J, Soler NG, “Mitotane. Spironolactone Antagonism in Cushing’s Syndrome,” <i>JAMA</i>, 1977, 238:2527. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=578890\">[PubMed 578890]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5375":"<p><b>Title</b> PrednisoLONE (Systemic) / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> PrednisoLONE (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of PrednisoLONE (Systemic). PrednisoLONE (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for changes in cyclosporine concentrations (likely an initial increase and possibly decreased thereafter), and for toxic effects of prednisolone and/or cyclosporine, if these agents are used concomitantly.</p> \n<p><b>Discussion</b> Several studies have reported decreased clearance of prednisolone (25% to 30%) in organ transplant recipients receiving cyclosporine.<sup>1,2,3</sup> Cushingoid symptoms have been seen in association with this interaction.<sup>4</sup> In like fashion, increased serum cyclosporine concentrations (as much as 100%) and decreased clearance have been reported in patients while receiving prednisone or methylprednisolone.<sup>4,5,6,7,8,9</sup><br><br>Although the preponderance of published evidence points to an interaction between cyclosporine and prednisolone, three small studies have not a shown significant drug interaction.<sup>10,11,12</sup> It has been proposed that the drug interaction may be dependent on dose, route, disease course, or other factors but these factors have not been the subject of further study.<br><br>While multiple animal and in vitro studies generally support these reported effects of cyclosporine on corticosteroid concentrations and/or distribution,<sup>13,14,15,16</sup> several animal studies have reported that concurrent administration of the glucocorticoids dexamethasone and methylprednisolone with cyclosporine was associated with decreased cyclosporine absorption and/or bioavailability,<sup>17,18,19</sup> increased cyclosporine metabolism and/or clearance,<sup>19,20,21</sup> and decreased cyclosporine concentrations.<sup>19,22</sup> Of note, one study found that only higher-dose dexamethasone was associated with an increased cyclosporine clearance and decreased cyclosporine concentrations after intravenous cyclosporine administration, whereas the bioavailability of orally administered cyclosporine was significantly reduced by both lower- and higher-dose dexamethasone.<sup>19</sup> This apparent dose-dependent impact is supported by the finding in other studies that only higher-dose steroids have a significant impact on CYP3A (enzyme that is at least partially responsible for cyclosporine metabolism) activity/expression.<sup>17,20</sup><br><br>The exact explanation for these discrepant findings regarding the impact of corticosteroids on cyclosporine pharmacokinetics is unknown. Initial inhibition of cyclosporine CYP3A metabolism via competitive inhibition by corticosteroids, which are also CYP3A substrates may explain the observed increases in cyclosporine concentrations after initiation of corticosteroids. With longer-term concurrent use, the expected effects include induction of p-glycoprotein-mediated cyclosporine efflux, resulting in decreased cyclosporine absorption/bioavailability (at both lower and higher steroid doses), and induction of cyclosporine metabolism via CYP3A (primarily in the intestine, and likely only observed at higher steroid doses).<br><br>The most likely mechanism of how cyclosporine impacts corticosteroids is inhibition of p-glycoprotein-mediated corticosteroid efflux by cyclosporine. As a result, steroid concentrations in plasma, specific tissues/organs (e.g., brain), and/or cells (e.g., lymphocytes) may be increased, including most notably in those tissues/cells that express high levels of p-glycoprotein.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Langhoff E, Madsen S, Olgaard K, et al, “Clinical Results and Cyclosporine Effect on Prednisolone Metabolism,” <i>Kidney Int</i>, 1984, 26:642. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3887391\">[PubMed 3887391]</a></p>\n<p>2. Langhoff E, Madsen S, Flachs H, et al, “Inhibition of Prednisolone Metabolism by Cyclosporine in Kidney-Transplanted Patients,” <i>Transplantation</i>, 1985, 39:107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3880958\">[PubMed 3880958]</a></p>\n<p>3. Ost L, “Impairment of Prednisolone Metabolism by Cyclosporine Treatment in Renal Graft Recipients,” <i>Transplantation</i>, 1987, 44(4):533-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3313841\">[PubMed 3313841]</a></p>\n<p>4. Ost L, Klintmalm G, and Ringden O, “Mutual Interaction between Prednisolone and Cyclosporine in Renal Transplant Patients,” <i>Transplant Proc</i>, 1985, 17:1252-5.</p>\n<p>5. Hricik DE, Moritz C, Mayes JT, et al, “Association of the Absence of Steroid Therapy With Increased Cyclosporine Blood Levels in Renal Transplant Recipients,” <i>Transplantation</i>, 1990, 49:221-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2301016\">[PubMed 2301016]</a></p>\n<p>6. Klintmalm G and Sawe J, “High Dose Methylprednisolone Increases Plasma Cyclosporine Levels in Renal Transplant Recipients,” <i>Lancet</i>, 1984, i:731. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6143058\">[PubMed 6143058]</a></p>\n<p>7. Durrant S, Chipping PM, Palmer S, et al, “Cyclosporine A, Methylprednisolone, and Convulsions,” <i>Lancet</i>, 1982, ii:829-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6126705\">[PubMed 6126705]</a></p>\n<p>8. Hall TG, “Effect of Methylprednisolone on Cyclosporine Blood Levels,” <i>Pharmacotherapy</i>, 1990, 10:248. </p>\n<p>9. Ptachcinski RJ, Venkataramanan R, Burckart GJ, et al, “Cyclosporine--High-Dose Steroid Interaction in Renal Transplant Recipients: Assessment by HPLC,” <i>Transplant Proc</i>, 1987, 19(1 Pt 2):1728-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3274417\">[PubMed 3274417]</a></p>\n<p>10. Frey FJ, Schnetzer A, Horber FF, et al, “Evidence that Cyclosporine Does Not Affect the Metabolism of Prednisolone after Renal Transplantation,” <i>Transplantation</i>, 1987, 43(4):494-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3554641\">[PubMed 3554641]</a></p>\n<p>11. Rocci ML Jr, Tietze KJ, Lee J, et al, “The Effect of Cyclosporine on the Pharmacokinetics of Prednisolone in Renal Transplant Patients,” <i>Transplantation</i>, 1988, 45(3):656-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3279590\">[PubMed 3279590]</a></p>\n<p>12. Arnold JC, O'Grady JG, Tredger JM, et al, “Effects of Low-Dose Prednisolone on Cyclosporine Pharmacokinetics in Liver Transplant Recipients: Radioimmunoassay with Specific and Non-Specific Monoclonal Antibodies,” <i>Eur J Clin Pharmacol</i>, 1990, 39(3):257-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2257862\">[PubMed 2257862]</a></p>\n<p>13. Bernards CM, “Cyclosporine-A-Mediated Inhibition of P-glycoprotein Increases Methylprednisolone Entry into the Central Nervous System,” <i>Spinal Cord</i>, 2006, 44(7):414-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16331311\">[PubMed 16331311]</a></p>\n<p>14. Mark PJ, Waddell BJ, “P-glycoprotein Restricts Access of Cortisol and Dexamethasone to the Glucocorticoid Receptor in Placental BeWo Cells,” <i>Endocrinology</i>, 2006, 147(11):5147-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16873536\">[PubMed 16873536]</a></p>\n<p>15. Tsujimura S, Saito K, Nakayamada S, et al, “Transcriptional Regulation of Multidrug Resistance-1 Gene by Interleukin-2 in Lymphocytes,” <i>Genes Cells</i>, 2004, 9(12):1265-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15569157\">[PubMed 15569157]</a></p>\n<p>16. Maillefert JF, Duchamp O, Solary E, et al, “Effects of Cyclosporin at Various Concentrations on Dexamethasone Intracellular Uptake in Multidrug Resistant Cells,” <i>Ann Rheum Dis</i>, 2000, 59(2):146-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10666173\">[PubMed 10666173]</a></p>\n<p>17. Jin M, Shimada T, Yokogawa K, et al, “Contributions of Intestinal P-glycoprotein and CYP3A to Oral Bioavailability of Cyclosporin A in Mice Treated With or Without Dexamethasone,” <i>Int J Pharm</i>, 2006, 309(1-2):81-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16384676\">[PubMed 16384676]</a></p>\n<p>18. Jin M, Shimada T, Yokogawa K, et al, “Site-Dependent Contributions of P-glycoprotein and CYP3A to Cyclosporin A Absorption, and Effect of Dexamethasone in Small Intestine of Mice,” <i>Biochem Pharmacol</i>, 2006, 72(8):1042-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16939683\">[PubMed 16939683]</a></p>\n<p>19. Yokogawa K, Shimada T, Higashi Y, et al, “Modulation of mdr1a and CYP3A Gene Expression in the Intestine and Liver as Possible Cause of Changes in the Cyclosporin A Disposition Kinetics by Dexamethasone,” <i>Biochem Pharmacol</i>, 2002, 63(4):777-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11992648\">[PubMed 11992648]</a></p>\n<p>20. Konishi H, Sumi M, Shibata N, et al, “Influence of Intravenous Methylprednisolone Pulse Treatment on the Disposition of Ciclosporin and Hepatic CYP3A Activity in Rats,” <i>J Pharm Pharmacol</i>, 2004, 56(4):477-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15099443\">[PubMed 15099443]</a></p>\n<p>21. Kolars JC, Stetson PL, Rush BD, et al, “Cyclosporine Metabolism by P450IIIA in Rat Enterocytes--Another Determinant of Oral Bioavailability?” <i>Transplantation</i>, 1992, 53(3):596-602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1549853\">[PubMed 1549853]</a></p>\n<p>22. Konishi H, Sumi M, Shibata N, et al, “Decrease in Oral Bioavailability of Ciclosporin by Intravenous Pulse of Methylprednisolone Succinate in Rats,” <i>J Pharm Pharmacol</i>, 2004, 56(10):1259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15482640\">[PubMed 15482640]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5377":"<p><b>Title</b> PredniSONE / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase serum concentrations of the active metabolite(s) of PredniSONE. PredniSONE may decrease the serum concentration of CycloSPORINE (Systemic). PredniSONE may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for changes in cyclosporine concentrations (likely an initial increase and possibly decreased thereafter), and for toxic effects of prednisone and/or cyclosporine, if these agents are used concomitantly.</p> \n<p><b>Discussion</b> Prednisolone is the primary active metabolite of prednisone in the body. Several studies have reported decreased clearance of prednisolone (25% to 30%) in organ transplant recipients receiving cyclosporine.<sup>1,2,3</sup> Cushingoid symptoms have been seen in association with this interaction.<sup>4</sup> In like fashion, increased serum cyclosporine concentrations (as much as 100%) and decreased clearance have been reported in patients while receiving prednisone or methylprednisolone.<sup>4,5,6,7,8,9</sup><br><br>Although the preponderance of published evidence points to an interaction between cyclosporine and prednisolone, three small studies have not a shown significant drug interaction.<sup>10,11,12</sup> It has been proposed that the drug interaction may be dependent on dose, route, disease course, or other factors but these factors have not been the subject of further study.<br><br>While multiple animal and in vitro studies generally support these reported effects of cyclosporine on corticosteroid concentrations and/or distribution,<sup>13,14,15,16</sup> several animal studies have reported that concurrent administration of the glucocorticoids dexamethasone and methylprednisolone with cyclosporine was associated with decreased cyclosporine absorption and/or bioavailability,<sup>17,18,19</sup> increased cyclosporine metabolism and/or clearance,<sup>19,20,21</sup> and decreased cyclosporine concentrations.<sup>19,22</sup> Of note, one study found that only higher-dose dexamethasone was associated with an increased cyclosporine clearance and decreased cyclosporine concentrations after intravenous cyclosporine administration, whereas the bioavailability of orally administered cyclosporine was significantly reduced by both lower- and higher-dose dexamethasone.<sup>19</sup> This apparent dose-dependent impact is supported by the finding in other studies that only higher-dose steroids have a significant impact on CYP3A (enzyme that is at least partially responsible for cyclosporine metabolism) activity/expression.<sup>17,20</sup><br><br>The exact explanation for these discrepant findings regarding the impact of corticosteroids on cyclosporine pharmacokinetics is unknown. Initial inhibition of cyclosporine CYP3A metabolism via competitive inhibition by corticosteroids, which are also CYP3A substrates may explain the observed increases in cyclosporine concentrations after initiation of corticosteroids. With longer-term concurrent use, the expected effects include induction of p-glycoprotein-mediated cyclosporine efflux, resulting in decreased cyclosporine absorption/bioavailability (at both lower and higher steroid doses), and induction of cyclosporine metabolism via CYP3A (primarily in the intestine, and likely only observed at higher steroid doses).<br><br>The most likely mechanism of how cyclosporine impacts corticosteroids is inhibition of p-glycoprotein-mediated corticosteroid efflux by cyclosporine. As a result, steroid concentrations in plasma, specific tissues/organs (e.g., brain), and/or cells (e.g., lymphocytes) may be increased, including most notably in those tissues/cells that express high levels of p-glycoprotein.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Langhoff E, Madsen S, Olgaard K, et al, “Clinical Results and Cyclosporine Effect on Prednisolone Metabolism,” <i>Kidney Int</i>, 1984, 26:642. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3887391\">[PubMed 3887391]</a></p>\n<p>2. Langhoff E, Madsen S, Flachs H, et al, “Inhibition of Prednisolone Metabolism by Cyclosporine in Kidney-Transplanted Patients,” <i>Transplantation</i>, 1985, 39:107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3880958\">[PubMed 3880958]</a></p>\n<p>3. Ost L, “Impairment of Prednisolone Metabolism by Cyclosporine Treatment in Renal Graft Recipients,” <i>Transplantation</i>, 1987, 44(4):533-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3313841\">[PubMed 3313841]</a></p>\n<p>4. Ost L, Klintmalm G, and Ringden O, “Mutual Interaction between Prednisolone and Cyclosporine in Renal Transplant Patients,” <i>Transplant Proc</i>, 1985, 17:1252-5.</p>\n<p>5. Hricik DE, Moritz C, Mayes JT, et al, “Association of the Absence of Steroid Therapy With Increased Cyclosporine Blood Levels in Renal Transplant Recipients,” <i>Transplantation</i>, 1990, 49:221-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2301016\">[PubMed 2301016]</a></p>\n<p>6. Klintmalm G and Sawe J, “High Dose Methylprednisolone Increases Plasma Cyclosporine Levels in Renal Transplant Recipients,” <i>Lancet</i>, 1984, i:731. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6143058\">[PubMed 6143058]</a></p>\n<p>7. Durrant S, Chipping PM, Palmer S, et al, “Cyclosporine A, Methylprednisolone, and Convulsions,” <i>Lancet</i>, 1982, ii:829-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6126705\">[PubMed 6126705]</a></p>\n<p>8. Hall TG, “Effect of Methylprednisolone on Cyclosporine Blood Levels,” <i>Pharmacotherapy</i>, 1990, 10:248. </p>\n<p>9. Ptachcinski RJ, Venkataramanan R, Burckart GJ, et al, “Cyclosporine--High-Dose Steroid Interaction in Renal Transplant Recipients: Assessment by HPLC,” <i>Transplant Proc</i>, 1987, 19(1 Pt 2):1728-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3274417\">[PubMed 3274417]</a></p>\n<p>10. Frey FJ, Schnetzer A, Horber FF, et al, “Evidence that Cyclosporine Does Not Affect the Metabolism of Prednisolone after Renal Transplantation,” <i>Transplantation</i>, 1987, 43(4):494-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3554641\">[PubMed 3554641]</a></p>\n<p>11. Rocci ML Jr, Tietze KJ, Lee J, et al, “The Effect of Cyclosporine on the Pharmacokinetics of Prednisolone in Renal Transplant Patients,” <i>Transplantation</i>, 1988, 45(3):656-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3279590\">[PubMed 3279590]</a></p>\n<p>12. Arnold JC, O'Grady JG, Tredger JM, et al, “Effects of Low-Dose Prednisolone on Cyclosporine Pharmacokinetics in Liver Transplant Recipients: Radioimmunoassay with Specific and Non-Specific Monoclonal Antibodies,” <i>Eur J Clin Pharmacol</i>, 1990, 39(3):257-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2257862\">[PubMed 2257862]</a></p>\n<p>13. Bernards CM, “Cyclosporine-A-Mediated Inhibition of P-glycoprotein Increases Methylprednisolone Entry into the Central Nervous System,” <i>Spinal Cord</i>, 2006, 44(7):414-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16331311\">[PubMed 16331311]</a></p>\n<p>14. Mark PJ, Waddell BJ, “P-glycoprotein Restricts Access of Cortisol and Dexamethasone to the Glucocorticoid Receptor in Placental BeWo Cells,” <i>Endocrinology</i>, 2006, 147(11):5147-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16873536\">[PubMed 16873536]</a></p>\n<p>15. Tsujimura S, Saito K, Nakayamada S, et al, “Transcriptional Regulation of Multidrug Resistance-1 Gene by Interleukin-2 in Lymphocytes,” <i>Genes Cells</i>, 2004, 9(12):1265-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15569157\">[PubMed 15569157]</a></p>\n<p>16. Maillefert JF, Duchamp O, Solary E, et al, “Effects of Cyclosporin at Various Concentrations on Dexamethasone Intracellular Uptake in Multidrug Resistant Cells,” <i>Ann Rheum Dis</i>, 2000, 59(2):146-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10666173\">[PubMed 10666173]</a></p>\n<p>17. Jin M, Shimada T, Yokogawa K, et al, “Contributions of Intestinal P-glycoprotein and CYP3A to Oral Bioavailability of Cyclosporin A in Mice Treated With or Without Dexamethasone,” <i>Int J Pharm</i>, 2006, 309(1-2):81-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16384676\">[PubMed 16384676]</a></p>\n<p>18. Jin M, Shimada T, Yokogawa K, et al, “Site-Dependent Contributions of P-glycoprotein and CYP3A to Cyclosporin A Absorption, and Effect of Dexamethasone in Small Intestine of Mice,” <i>Biochem Pharmacol</i>, 2006, 72(8):1042-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16939683\">[PubMed 16939683]</a></p>\n<p>19. Yokogawa K, Shimada T, Higashi Y, et al, “Modulation of mdr1a and CYP3A Gene Expression in the Intestine and Liver as Possible Cause of Changes in the Cyclosporin A Disposition Kinetics by Dexamethasone,” <i>Biochem Pharmacol</i>, 2002, 63(4):777-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11992648\">[PubMed 11992648]</a></p>\n<p>20. Konishi H, Sumi M, Shibata N, et al, “Influence of Intravenous Methylprednisolone Pulse Treatment on the Disposition of Ciclosporin and Hepatic CYP3A Activity in Rats,” <i>J Pharm Pharmacol</i>, 2004, 56(4):477-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15099443\">[PubMed 15099443]</a></p>\n<p>21. Kolars JC, Stetson PL, Rush BD, et al, “Cyclosporine Metabolism by P450IIIA in Rat Enterocytes--Another Determinant of Oral Bioavailability?” <i>Transplantation</i>, 1992, 53(3):596-602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1549853\">[PubMed 1549853]</a></p>\n<p>22. Konishi H, Sumi M, Shibata N, et al, “Decrease in Oral Bioavailability of Ciclosporin by Intravenous Pulse of Methylprednisolone Succinate in Rats,” <i>J Pharm Pharmacol</i>, 2004, 56(10):1259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15482640\">[PubMed 15482640]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5380":"<p><b>Title</b> MethylPREDNISolone / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of MethylPREDNISolone. MethylPREDNISolone may increase the serum concentration of CycloSPORINE (Systemic). MethylPREDNISolone may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for changes in cyclosporine concentrations (likely an initial increase and possibly decreased thereafter), and for toxic effects of methylprednisolone and/or cyclosporine, if these agents are used concomitantly.</p> \n<p><b>Discussion</b> Several studies have reported decreased clearance of prednisolone (25% to 30%) in organ transplant recipients receiving cyclosporine.<sup>1,2,3</sup> Cushingoid symptoms have been seen in association with this interaction.<sup>4</sup> In like fashion, increased serum cyclosporine concentrations (as much as 100%) and decreased clearance have been reported in patients while receiving prednisone or methylprednisolone.<sup>4,5,6,7,8,9</sup><br><br>Although the preponderance of published evidence points to an interaction between cyclosporine and prednisolone, three small studies have not a shown significant drug interaction.<sup>10,11,12</sup> It has been proposed that the drug interaction may be dependent on dose, route, disease course, or other factors but these factors have not been the subject of further study.<br><br>While multiple animal and in vitro studies generally support these reported effects of cyclosporine on corticosteroid concentrations and/or distribution,<sup>13,14,15,16</sup> several animal studies have reported that concurrent administration of the glucocorticoids dexamethasone and methylprednisolone with cyclosporine was associated with decreased cyclosporine absorption and/or bioavailability,<sup>17,18,19</sup> increased cyclosporine metabolism and/or clearance,<sup>19,20,21</sup> and decreased cyclosporine concentrations.<sup>19,22</sup> Of note, one study found that only higher-dose dexamethasone was associated with an increased cyclosporine clearance and decreased cyclosporine concentrations after intravenous cyclosporine administration, whereas the bioavailability of orally administered cyclosporine was significantly reduced by both lower- and higher-dose dexamethasone.<sup>19</sup> This apparent dose-dependent impact is supported by the finding in other studies that only higher-dose steroids have a significant impact on CYP3A (enzyme that is at least partially responsible for cyclosporine metabolism) activity/expression.<sup>17,20</sup><br><br>The exact explanation for these discrepant findings regarding the impact of corticosteroids on cyclosporine pharmacokinetics is unknown. Initial inhibition of cyclosporine CYP3A metabolism via competitive inhibition by corticosteroids, which are also CYP3A substrates may explain the observed increases in cyclosporine concentrations after initiation of corticosteroids. With longer-term concurrent use, the expected effects include induction of p-glycoprotein-mediated cyclosporine efflux, resulting in decreased cyclosporine absorption/bioavailability (at both lower and higher steroid doses), and induction of cyclosporine metabolism via CYP3A (primarily in the intestine, and likely only observed at higher steroid doses).<br><br>The most likely mechanism of how cyclosporine impacts corticosteroids is inhibition of p-glycoprotein-mediated corticosteroid efflux by cyclosporine. As a result, steroid concentrations in plasma, specific tissues/organs (e.g., brain), and/or cells (e.g., lymphocytes) may be increased, including most notably in those tissues/cells that express high levels of p-glycoprotein.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Langhoff E, Madsen S, Olgaard K, et al, “Clinical Results and Cyclosporine Effect on Prednisolone Metabolism,” <i>Kidney Int</i>, 1984, 26:642. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3887391\">[PubMed 3887391]</a></p>\n<p>2. Langhoff E, Madsen S, Flachs H, et al, “Inhibition of Prednisolone Metabolism by Cyclosporine in Kidney-Transplanted Patients,” <i>Transplantation</i>, 1985, 39:107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3880958\">[PubMed 3880958]</a></p>\n<p>3. Ost L, “Impairment of Prednisolone Metabolism by Cyclosporine Treatment in Renal Graft Recipients,” <i>Transplantation</i>, 1987, 44(4):533-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3313841\">[PubMed 3313841]</a></p>\n<p>4. Ost L, Klintmalm G, and Ringden O, “Mutual Interaction between Prednisolone and Cyclosporine in Renal Transplant Patients,” <i>Transplant Proc</i>, 1985, 17:1252-5.</p>\n<p>5. Hricik DE, Moritz C, Mayes JT, et al, “Association of the Absence of Steroid Therapy With Increased Cyclosporine Blood Levels in Renal Transplant Recipients,” <i>Transplantation</i>, 1990, 49:221-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2301016\">[PubMed 2301016]</a></p>\n<p>6. Klintmalm G and Sawe J, “High Dose Methylprednisolone Increases Plasma Cyclosporine Levels in Renal Transplant Recipients,” <i>Lancet</i>, 1984, i:731. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6143058\">[PubMed 6143058]</a></p>\n<p>7. Durrant S, Chipping PM, Palmer S, et al, “Cyclosporine A, Methylprednisolone, and Convulsions,” <i>Lancet</i>, 1982, ii:829-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6126705\">[PubMed 6126705]</a></p>\n<p>8. Hall TG, “Effect of Methylprednisolone on Cyclosporine Blood Levels,” <i>Pharmacotherapy</i>, 1990, 10:248. </p>\n<p>9. Ptachcinski RJ, Venkataramanan R, Burckart GJ, et al, “Cyclosporine--High-Dose Steroid Interaction in Renal Transplant Recipients: Assessment by HPLC,” <i>Transplant Proc</i>, 1987, 19(1 Pt 2):1728-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3274417\">[PubMed 3274417]</a></p>\n<p>10. Frey FJ, Schnetzer A, Horber FF, et al, “Evidence that Cyclosporine Does Not Affect the Metabolism of Prednisolone after Renal Transplantation,” <i>Transplantation</i>, 1987, 43(4):494-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3554641\">[PubMed 3554641]</a></p>\n<p>11. Rocci ML Jr, Tietze KJ, Lee J, et al, “The Effect of Cyclosporine on the Pharmacokinetics of Prednisolone in Renal Transplant Patients,” <i>Transplantation</i>, 1988, 45(3):656-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3279590\">[PubMed 3279590]</a></p>\n<p>12. Arnold JC, O'Grady JG, Tredger JM, et al, “Effects of Low-Dose Prednisolone on Cyclosporine Pharmacokinetics in Liver Transplant Recipients: Radioimmunoassay with Specific and Non-Specific Monoclonal Antibodies,” <i>Eur J Clin Pharmacol</i>, 1990, 39(3):257-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2257862\">[PubMed 2257862]</a></p>\n<p>13. Bernards CM, “Cyclosporine-A-Mediated Inhibition of P-glycoprotein Increases Methylprednisolone Entry into the Central Nervous System,” <i>Spinal Cord</i>, 2006, 44(7):414-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16331311\">[PubMed 16331311]</a></p>\n<p>14. Mark PJ, Waddell BJ, “P-glycoprotein Restricts Access of Cortisol and Dexamethasone to the Glucocorticoid Receptor in Placental BeWo Cells,” <i>Endocrinology</i>, 2006, 147(11):5147-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16873536\">[PubMed 16873536]</a></p>\n<p>15. Tsujimura S, Saito K, Nakayamada S, et al, “Transcriptional Regulation of Multidrug Resistance-1 Gene by Interleukin-2 in Lymphocytes,” <i>Genes Cells</i>, 2004, 9(12):1265-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15569157\">[PubMed 15569157]</a></p>\n<p>16. Maillefert JF, Duchamp O, Solary E, et al, “Effects of Cyclosporin at Various Concentrations on Dexamethasone Intracellular Uptake in Multidrug Resistant Cells,” <i>Ann Rheum Dis</i>, 2000, 59(2):146-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10666173\">[PubMed 10666173]</a></p>\n<p>17. Jin M, Shimada T, Yokogawa K, et al, “Contributions of Intestinal P-glycoprotein and CYP3A to Oral Bioavailability of Cyclosporin A in Mice Treated With or Without Dexamethasone,” <i>Int J Pharm</i>, 2006, 309(1-2):81-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16384676\">[PubMed 16384676]</a></p>\n<p>18. Jin M, Shimada T, Yokogawa K, et al, “Site-Dependent Contributions of P-glycoprotein and CYP3A to Cyclosporin A Absorption, and Effect of Dexamethasone in Small Intestine of Mice,” <i>Biochem Pharmacol</i>, 2006, 72(8):1042-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16939683\">[PubMed 16939683]</a></p>\n<p>19. Yokogawa K, Shimada T, Higashi Y, et al, “Modulation of mdr1a and CYP3A Gene Expression in the Intestine and Liver as Possible Cause of Changes in the Cyclosporin A Disposition Kinetics by Dexamethasone,” <i>Biochem Pharmacol</i>, 2002, 63(4):777-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11992648\">[PubMed 11992648]</a></p>\n<p>20. Konishi H, Sumi M, Shibata N, et al, “Influence of Intravenous Methylprednisolone Pulse Treatment on the Disposition of Ciclosporin and Hepatic CYP3A Activity in Rats,” <i>J Pharm Pharmacol</i>, 2004, 56(4):477-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15099443\">[PubMed 15099443]</a></p>\n<p>21. Kolars JC, Stetson PL, Rush BD, et al, “Cyclosporine Metabolism by P450IIIA in Rat Enterocytes--Another Determinant of Oral Bioavailability?” <i>Transplantation</i>, 1992, 53(3):596-602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1549853\">[PubMed 1549853]</a></p>\n<p>22. Konishi H, Sumi M, Shibata N, et al, “Decrease in Oral Bioavailability of Ciclosporin by Intravenous Pulse of Methylprednisolone Succinate in Rats,” <i>J Pharm Pharmacol</i>, 2004, 56(10):1259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15482640\">[PubMed 15482640]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5381":"<p><b>Title</b> Calcium Channel Blockers (Nondihydropyridine) / Calcium Channel Blockers (Dihydropyridine)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic/toxic effects of dihydropyridine calcium channel blockers if diltiazem or verapamil are initiated/dose increased, or decreased effects if diltiazem or verapamil are discontinued/dose decreased.</p>\n<div>\n <p><b>Calcium Channel Blockers (Dihydropyridine) Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Cilnidipine, Clevidipine, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine</p>\n <p><b>Calcium Channel Blockers (Nondihydropyridine) Interacting Members</b> Bepridil, DilTIAZem, Verapamil</p>\n</div> \n<p><b>Discussion</b> Several case reports and clinical studies describe toxic effects of combinations of nondihydropyridine calcium channel antagonists with dihydropyridine calcium channel antagonists.<sup>1,2,3,4,5,6</sup> Toxicities have included hypotension, tachycardia, dizziness, ankle edema, and paralytic ileus.<br><br>In a clinical study of 6 healthy volunteers, pretreatment with diltiazem (180 mg/day orally) increased the AUC (a measure of drug exposure) of nifedipine (20 mg single oral dose) by an average of 140%.<sup>7</sup> This was accompanied by greater decreases in blood pressure than were seen with nifedipine alone. In follow-up studies, the authors demonstrated trends toward a greater magnitude of drug interaction with increasing dose of diltiazem (90 mg 4 times daily vs. 30 mg 4 times daily) and with increasing duration of diltiazem pretreatment (30 mg 4 times daily for 1 day vs. 3 days vs. 6 days).<sup>8,9</sup> In patients with angina, nifedipine serum concentrations (10 mg 4 times daily for 1 week) increased approximately 3-fold in 11 patients when coadministered with diltiazem (30 mg 4 times daily for 1 week).<sup>10</sup> In a study of 5 healthy volunteers, it was also shown that nifedipine pretreatment (30 mg/day orally for 3 days) increased the maximum concentration and AUC of diltiazem by approximately 55% and 49%, respectively, although the change in AUC was not statistically significant (P between 0.05 and 0.10).<sup>11</sup> Heart rate was higher in the nifedipine-pretreated subjects in the first 3 hours post-diltiazem dose.<br><br>In a clinical study, 16 hypertensive adults were given nifedipine sustained release (30 mg/day) for two weeks and assigned to subsequently receive two weeks of verapamil and two weeks of diltiazem, both 180 mg/day sustained release for two weeks, in random order.<sup>12</sup> Verapamil and diltiazem both increased nifedipine AUC, but the magnitude of increase was significantly greater with diltiazem than with verapamil (49% vs. 18% increase). Both combinations decreased blood pressure more than nifedipine alone, and there was a trend toward greater decreases with diltiazem. <br><br>The AUC of amlodipine (5 mg single dose) was increased 57% in 8 patients when administered following a 3-day course of diltiazem (180 mg/day).<sup>13</sup><br><br>Interactions between dihydropyridine and nondihydropyridine calcium channel blockers likely occur at several levels. Diltiazem and verapamil likely inhibit the CYP3A4-mediated metabolism of the dihydropyridines, leading to the demonstrated increases in dihydropyridine exposure. Dihydropyridines have not clearly been shown to increase nondihydropyridine concentrations, although particular caution may be warranted with nicardipine (a potent CYP3A4 inhibitor). Antihypertensive properties of dihydropyridine and nondihydropyridine calcium channel antagonists are also likely enhanced by their combination. Despite the multiple levels of potential interaction between these groups of agents, a number of case reports and clinical studies have shown successful combination therapy with dihydropyridines and nondihydropyridines without apparent increases in toxicity, with or without pre-emptive dihydropyridine dose reductions,.<sup>14,15,16,17,18,19,20,21,22,23,24</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Karotsis AK, Symeonidis A, Mastorantonakis SE, et al, “Additional Antihypertensive Effect of Drugs in Hypertensive Subjects Uncontrolled on Diltiazem Monotherapy: A Randomized Controlled Trial Using Office and Home Blood Pressure Monitoring,” <i>Clin Exp Hypertens</i>, 2006, 28(7):655-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17060064\">[PubMed 17060064]</a></p>\n<p>2. Harada T, Ohtaki E, Sumiyoshi T, et al, “Paralytic Ileus Induced by the Combined Use of Nifedipine and Diltiazem in the Treatment of Vasospastic Angina,” <i>Cardiology</i>, 2002, 97(2):113-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11978960\">[PubMed 11978960]</a></p>\n<p>3. Pucci PD, Pollavini G, Zerauscheck M, et al, “Acute Effects on Exercise Tolerance of Felodipine and Diltiazem, Alone and in Combination, in Stable Effort Angina,” <i>Eur Heart J</i>, 1991, 12(1):55-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2009894\">[PubMed 2009894]</a></p>\n<p>4. Kaesemeyer WH, Carr AA, Bottini PB, et al, “Verapamil and Nifedipine in Combination for the Treatment of Hypertension,” <i>J Clin Pharmacol</i>, 1994, 34(1):48-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8132851\">[PubMed 8132851]</a></p>\n<p>5. Prida XE, Gelman JS, Feldman RL, et al, “Comparison of Diltiazem and Nifedipine Alone and in Combination in Patients with Coronary Artery Spasm,” <i>J Am Coll Cardiol</i>, 1987, 9(2):412-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3543092\">[PubMed 3543092]</a></p>\n<p>6. Frishman W, Charlap S, Kimmel B, et al, “Diltiazem, Nifedipine, and Their Combination in Patients with Stable Angina Pectoris: Effects on Angina, Exercise Tolerance, and the Ambulatory Electrocardiographic ST Segment,” <i>Circulation</i>, 1988, 77(4):774-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3280158\">[PubMed 3280158]</a></p>\n<p>7. Ohashi K, Tateishi T, Sudo T, et al, “Effects of Diltiazem on the Pharmacokinetics of Nifedipine,” <i>J Cardiovasc Pharmacol</i>, 1990, 15(1):96-101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1688989\">[PubMed 1688989]</a></p>\n<p>8. Ohashi K, Sudo T, Sakamoto K, et al, “The Influence of Pretreatment Periods with Diltiazem on Nifedipine Kinetics,” <i>J Clin Pharmacol</i>, 1993, 33(3):222-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8463435\">[PubMed 8463435]</a></p>\n<p>9. Tateishi T, Ohashi K, Sudo T, et al, “Dose Dependent Effect of Diltiazem on the Pharmacokinetics of Nifedipine,” <i>J Clin Pharmacol</i>, 1989, 29(11):994-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2600195\">[PubMed 2600195]</a></p>\n<p>10. Toyosaki N, Toyo-oka T, Natsume T, et al, “Combination Therapy With Diltiazem and Nifedipine in Patients With Effort Angina Pectoris,” <i>Circulation</i>, 1988, 77(6):1370-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3286041\">[PubMed 3286041]</a></p>\n<p>11. Tateishi T, Ohashi K, Sudo T, et al, “The Effect of Nifedipine on the Pharmacokinetics and Dynamics of Diltiazem: The Preliminary Study in Normal Volunteers,” <i>J Clin Pharmacol</i>, 1993, 33(8):738-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8408735\">[PubMed 8408735]</a></p>\n<p>12. Saseen JJ, Carter BL, Brown TE, et al, “Comparison of Nifedipine Alone and with Diltiazem or Verapamil in Hypertension,” <i>Hypertension</i>, 1996, 28(1):109-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8675249\">[PubMed 8675249]</a></p>\n<p>13. Sasaki M, Maeda A, and Fujimura A, “Influence of Diltiazem on the Pharmacokinetics of Amlodipine in Elderly Hypertensive Patients,” <i>Eur J Clin Pharmacol</i>, 2001, 57(1):85-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11372598\">[PubMed 11372598]</a></p>\n<p>24. Busse JC, de Velasco RE and Pellegrini EL, “Combined Use of Nifedipine and Diltiazem for the Treatment of Severe Hypertension,” <i>South Med J</i>, 1991, 84(4):502-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2014439\">[PubMed 2014439]</a></p>\n<p>15. Andreyev N, Bichkov I, Skutelis A, et al, “Comparison of Diltiazem, Nitrendipine, and their Combination for Systemic Hypertension and Stable Angina Pectoris,” <i>J Cardiovasc Pharmacol</i>, 1991, 18 Suppl 9:S73-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1725550\">[PubMed 1725550]</a></p>\n<p>16. Geurian K and Lipschitz D, “Successful Management of Refractory Hypertension with Dual Calcium Channel Blocker Therapy: Case Presentation,” <i>Arch Fam Med</i>, 1997, 6(5):503-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9305698\">[PubMed 9305698]</a></p>\n<p>17. Handler J, “Case Studies in Hypertension. Dihydropyridine/Nondihydropyridine Calcium Channel Blocker Combination Therapy,” <i>J Clin Hypertens (Greenwich)</i>, 2005, 7(1):50-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15655389\">[PubMed 15655389]</a></p>\n<p>18. Tsutsui T, “Combined Administration of Diltiazem and Nicardipine Attenuates Hypertensive Responses to Emergence and Extubation,” <i>J Neurosurg Anesthesiol</i>, 2002, 14(2):89-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11907387\">[PubMed 11907387]</a></p>\n<p>19. Goldberger J and Frishman WH, “Clinical Utility of Nifedipine and Diltiazem Plasma Levels in Patients with Angina Pectoris Receiving Monotherapy and Combination Treatment,” <i>J Clin Pharmacol</i>, 1989, 29(7):628-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2760256\">[PubMed 2760256]</a></p>\n<p>20. Ikeda Y, Sakemi T, Yamada M, et al, “Successful Combined Therapy of Nifedipine and Diltiazem for Severe Hypertension in a Maintenance Hemodialysis Patient,” <i>Clin Nephrol</i>, 1999, 51(2):127-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10069650\">[PubMed 10069650]</a></p>\n<p>21. Kaesemeyer WH, Prisant LM and Carr AA, “Verapamil and Nifedipine in Combination for the Treatment of Hypertrophy Heart Disease,” <i>Am J Hypertens</i>, 1991 4(10 Pt 1):866-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1747220\">[PubMed 1747220]</a></p>\n<p>22. De Caprio L, Acanfora D, Odierna L, et al, “Acute Effects of Nifedipine, Diltiazem and Their Combination in Patients with Chronic Stable Angina: A Double-Blind, Randomized, Cross-Over, Placebo-Controlled Study,” <i> Eur Heart J</i>, 1993, 14(3):416-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8458364\">[PubMed 8458364]</a></p>\n<p>23. Nalbantgil I, Onder R, Kiliccioglu B, et al, “Combination Therapy with Verapamil and Nitrendipine in Patients with Hypertension,” <i>J Hum Hypertens</i>, 1993, 7(3):305-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8345499\">[PubMed 8345499]</a></p>\n<p>24. Carver JR, Spitzer S, Mason D, et al, “Diltiazem, Nifedipine Combination in Coronary Artery Spasm,” <i>Chest</i>, 1984, 85(2):296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6692719\">[PubMed 6692719]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5382":"<p><b>Title</b> Lumefantrine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for potential increased toxicity of lumefantrine (including QT interval prolongation) when used in combination with strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Co-administration of the strong CYP3A4 inhibitor darunavir/ritonavir (600 mg /100 mg twice/day, days 1-21) with artemether/lumefantrine (80 mg/480 mg x 6 doses, days 8-11) decreased the average AUC of artemether 16%, decreased the average AUC of its active metabolite dihydroartemisinin 18%, and increased the average AUC of lumefantrine 2.75-fold in a study of 16 healthy volunteers.<sup>1</sup> One subject experienced a QTc of more than 450 ms with co-administration, but no subject had a change in QTc of greater than 60 ms. <br><br>In another clinical study of 15 healthy volunteers, administration of the strong CYP3A4 inhibitor ketoconazole (800 mg orally on day 1, then 200 mg once daily on days 2-5) with a single oral dose of artemether/lumefantrine (80/480 mg on day 1) increased the average AUC of lumefantrine approximately 1.7-fold.<sup>2</sup> Blood samples for pharmacokinetic analysis were drawn until day 11. In a clinical study of 10 healthy volunteers, steady-state dosing of the CYP3A4 inhibitor lopinavir/ritonavir (400 mg/100 mg orally twice daily) increased the AUC of lumefantrine (artemether/lumefantrine 80 mg/480 mg orally twice daily x 6 doses) by approximately 2-fold.<sup>3</sup> Sampling for pharmacokinetic analysis began with the sixth dose of artemether/lumefantrine and continued for 11 days. Lopinavir/ritonavir dosing was continued until pharmacokinetic sampling was complete.<br><br>Inhibition of CYP3A4 mediated lumefantrine metabolism is presumed to be the primary mechanism of the pharmacokinetic interaction observed with these combinations.<sup>4</sup> In vitro studies using human liver microsomes and recombinant CYP450 enzymes indicate that lumefantrine is primarily metabolized by CYP3A4. A possible contribution of other enzymes or transporters to the observed interactions with CYP3A4 inhibitors, particularly P-glycoprotein, cannot be ruled out.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kakuda T, Demasi R, van Delft Y, et al, “Pharmacokinetic Interaction between Etravirine or Darunavir/Ritonavir and Artemether/Lumefantrine in Healthy Volunteers: A Two-Panel, Two-Way, Two-Period, Randomized Trial,” <i>HIV Med</i>, 2013, Feb 26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23441978\">[PubMed 23441978]</a></p>\n<p>2. Lefevre G, Carpenter P, Souppart C, et al, “Pharmacokinetics and Electrocardiographic Pharmacodynamics of Artemether-Lumefantrine (Riamet) with Concomitant Administration of Ketoconazole in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2002, 54(5):485-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12445027\">[PubMed 12445027]</a></p>\n<p>3. German P, Parikh S, Lawrence J, et al, “Lopinavir/Ritonavir Affects Pharmacokinetic Exposure of Artemether/Lumefantrine in HIV-Uninfected Healthy Volunteers,” <i>J Acquir Immune Defic Syndr</i>, 2009, 51(4):424-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19506482\">[PubMed 19506482]</a></p>\n<p>4. Prescribing information. Coartem (artemether/lumefantrine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, February 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5383":"<p><b>Title</b> CarBAMazepine / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving both a thiazide diuretic and carbamazepine should be monitored closely for signs/symptoms of hyponatremia (e.g., nausea, headache, confusion, lethargy).</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Case reports describe several patients who developed symptomatic hyponatremia while receiving concurrent carbamazepine and a diuretic.<sup>1,2</sup> Shortly after discontinuation of one or both agents, hyponatremic symptoms resolved and serum sodium concentrations improved in all patients.<br><br>Both diuretics and carbamazepine are independently associated with a risk of hyponatremia. Of all diuretics, thiazides appear to have the greatest risk of causing hyponatremia. A review of 129 reported cases of diuretic-associated hyponatremia found 63% of the cases were due to administration of a thiazide and a further 10% due to the thiazide-like diuretic chlorthalidone.<sup>3</sup> Additional case reports of thiazide-like diuretics (chlorthalidone, metolazone) as a possible cause of/contributor to hyponatremia, have also been mentioned in the literature.<sup>4,5</sup> The mechanism of thiazide induced hyponatremia is thought to be due to inhibition of sodium reabsorption at the distal renal tubules. Although some discrepancies exist, it is possible that advanced age may be a predisposing cause to hyponatremia.<sup>6</sup> Analysis of case reports also identified women as four times more likely than men to experience diuretic induced hyponatremia.<sup>3</sup><br><br>Similarily, an increased risk of hyponatremia has been associated with carbamazepine use, either alone or in combination with other sodium wasting drugs. Several reviews of carbamazepine-associated hyponatremia that summarize reported cases and examine potential risk factors have been published.<sup>7,8</sup> The mechanism by which carbamazepine causes hyponatremia is thought to be potentiation of the actions of antidiuretic hormone leading to dilutional hyponatremia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ranta A, Wooten GF, “Hyponatremia Due to an Additive Effect of Carbamazepine and Thiazide Diuretics,” <i>Epilepsia</i>, 2004, 4(7):879. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15230718\">[PubMed 15230718]</a></p>\n<p>2. Yassa R, Nastase C, Camille Y, et al, “Carbamazepine, Diuretics, and Hyponatremia: A Possible Interaction,” <i>J Clin Psychiatry</i>, 1987;48:281-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3597330\">[PubMed 3597330]</a></p>\n<p>3. Sonnenblick M, Friedlander Y, Rosin AJ, “Diuretic-Induced Severe Hyponatremia. Review and Analysis of 129 Reported Patients,” <i>Chest</i>, 1993, 103:601-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8432162\">[PubMed 8432162]</a></p>\n<p>4. Luboshitzky R, Tal-Or Z, Barzilai D, “Chlorthalidone-Induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone,” <i>J Clin Pharmacol</i>, 1978, 18:336-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=670429\">[PubMed 670429]</a></p>\n<p>5. Ashraf N, Locksley R, Arieff AI, “Thiazide-Induced Hyponatremia Associated with Death or Neurologic Damage in Outpatients,” <i>Am J Med</i>, 1981, 70(6):1163-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7234886\">[PubMed 7234886]</a></p>\n<p>6. Chow KM, Szeto CC, Wong TY, et al, “Risk Factors for Thiazide-Induced Hyponatremia,” <i>QJM</i>, 2003, 96:911-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14631057\">[PubMed 14631057]</a></p>\n<p>7. Gandelman MS, “Review of Carbamazepine-Induced Hyponatremia,” <i>Prog Neuropsychopharmacol Biol Psychiatry</i>, 1994, 18(2):211-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8208974\">[PubMed 8208974]</a></p>\n<p>8. Van Amelsvoort T, Bakshi R, Devaux CB, et al, “Hyponatremia Associated with Carbamazepine and Oxcarbazepine Therapy: A Review,” <i>Epilepsia</i>, 1994, 35(1):181-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8112243\">[PubMed 8112243]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5384":"<p><b>Title</b> OXcarbazepine / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving both a thiazide diuretic and oxcarbazepine should be monitored closely for signs/symptoms of hyponatremia (e.g., nausea, headache, confusion, lethargy).</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Although there are no specific reports of an oxcarbazepine-diuretic interaction, several reports of such an interaction involving the related drug carbamazepine have been published,<sup>1,2</sup> and some evidence suggests oxcarbazepine is at least as likely to cause such an interaction.<sup>3,4</sup><br><br>Case reports describe several patients who developed symptomatic hyponatremia while receiving concurrent carbamazepine and a diuretic.<sup>1,2</sup> Shortly after discontinuation of one or both agents, hyponatremic symptoms resolved and serum sodium concentrations improved in all patients.<br><br>Both diuretics and carbamazepine/oxcarbazepine are independently associated with a risk of hyponatremia. Of all diuretics, thiazides appear to have the greatest risk of causing hyponatremia. A review of 129 reported cases of diuretic-associated hyponatremia found 63% of the cases were due to administration of a thiazide and a further 10% due to the thiazide-like diuretic chlorthalidone.<sup>5</sup> Additional case reports of thiazide-like diuretics (chlorthalidone, metolazone) as a possible cause of/contributor to hyponatremia, have also been mentioned in the literature.<sup>6,7</sup> The mechanism of thiazide induced hyponatremia is thought to be due to inhibition of sodium reabsorption at the distal renal tubules. Although some discrepancies exist, it is possible that advanced age may be a predisposing cause to hyponatremia.<sup>8</sup> Analysis of case reports also identified women as four times more likely than men to experience diuretic induced hyponatremia.<sup>5</sup><br><br>Similarily, an increased risk of hyponatremia has been associated with oxcarbazepine use. According to the oxcarbazepine prescribing information, an analysis of 14 studies concluded that 2.5% of patients experienced clinically important hyponatremia during oxcarbazepine therapy.<sup>3</sup> Compared to treatment with carbamazepine, serum sodium concentrations were lower during treatment with oxcarbazepine in a randomized, crossover study of 48 patients, though no patients experienced clinically significant hyponatremia with either treatment.<sup>4</sup> Several reviews of oxcarbazepine- and/or carbamazepine-associated hyponatremia that summarize reported cases and examine potential risk factors have been published.<sup>9,10</sup> The mechanism by which oxcarbazepine (and carbamazepine) causes hyponatremia is thought to be potentiation of the actions of antidiuretic hormone leading to dilutional hyponatremia.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ranta A, Wooten GF, “Hyponatremia Due to an Additive Effect of Carbamazepine and Thiazide Diuretics,” <i>Epilepsia</i>, 2004, 4(7):879. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15230718\">[PubMed 15230718]</a></p>\n<p>2. Yassa R, Nastase C, Camille Y, et al, “Carbamazepine, Diuretics, and Hyponatremia: A Possible Interaction,” <i>J Clin Psychiatry</i>, 1987;48:281-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3597330\">[PubMed 3597330]</a></p>\n<p>3. Prescribing information. Trileptal (oxcarbazepine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, February 2009.</p>\n<p>4. Houtkooper MA, Lammertsma A, Meyer JW, et al, “Oxcarbazepine (GP 47.680): A Possible Alternative to Carbamazepine?” <i>Epilepsia</i>, 1987, 28(6):693-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3319537\">[PubMed 3319537]</a></p>\n<p>5. Sonnenblick M, Friedlander Y, Rosin AJ, “Diuretic-Induced Severe Hyponatremia. Review and Analysis of 129 Reported Patients,” <i>Chest</i>, 1993, 103:601-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8432162\">[PubMed 8432162]</a></p>\n<p>6. Luboshitzky R, Tal-Or Z, Barzilai D, “Chlorthalidone-Induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone,” <i>J Clin Pharmacol</i>, 1978, 18:336-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=670429\">[PubMed 670429]</a></p>\n<p>7. Ashraf N, Locksley R, Arieff AI, “Thiazide-Induced Hyponatremia Associated with Death or Neurologic Damage in Outpatients,” <i>Am J Med</i>, 1981, 70(6):1163-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7234886\">[PubMed 7234886]</a></p>\n<p>8. Chow KM, Szeto CC, Wong TY, et al, “Risk Factors for Thiazide-Induced Hyponatremia,” <i>QJM</i>, 2003, 96:911-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14631057\">[PubMed 14631057]</a></p>\n<p>9. Van Amelsvoort T, Bakshi R, Devaux CB, et al, “Hyponatremia Associated with Carbamazepine and Oxcarbazepine Therapy: A Review,” <i>Epilepsia</i>, 1994, 35(1):181-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8112243\">[PubMed 8112243]</a></p>\n<p>10. Gandelman MS, “Review of Carbamazepine-Induced Hyponatremia,” <i>Prog Neuropsychopharmacol Biol Psychiatry</i>, 1994, 18(2):211-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8208974\">[PubMed 8208974]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5385":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Dipeptidyl Peptidase-IV Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dipeptidyl Peptidase-IV Inhibitors may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Note that use of this combination may increase the risk for angioedema. Educate patients regarding this risk and advise them to report any signs or symptoms of angioedema immediately. Angioedema may appear at any time during concurrent use, including after months or years on the combination.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Dipeptidyl Peptidase-IV Inhibitors Interacting Members</b> Alogliptin, Anagliptin, Evogliptin, Gemigliptin, Linagliptin, SAXagliptin, SITagliptin, Teneligliptin, Vildagliptin</p>\n</div> \n<p><b>Discussion</b> The odds of developing angioedema were 4.6 times greater with concurrent use of the dipeptidyl peptidase-IV (DPPIV) inhibitor vildagliptin (not available in the U.S., but available in Europe) with an angiotensin converting enzyme (ACE) inhibitor versus concurrent use of a comparator (placebo, metformin, pioglitazone, rosiglitazone, glimepiride, or acarbose) plus an ACE inhibitor in a retrospective analysis of data from several different vildagliptin trials.<sup>1</sup> The increased odds were only significant at vildagliptin doses of 100 mg/d.<br><br>Prescribing information for the DPPIV inhibitors available in the U.S. do not specifically warn about this potential interaction, but they do caution about possible angioedema and/or facial edema possible with these agents.<sup>2,3</sup><br><br>The mechanism of this possible interaction is thought to be synergistic inhibition of substance P metabolism leading to increased concentrations of substance P. The resultant accumulation of substance P can then cause increased vascular permeability and edema.<sup>1,4</sup> Both DPPIV and ACE are normally involved in the metabolism of substance P, with DPPIV activity serving an important role only when ACE activity is diminished.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brown NJ, Byiers S, Carr D, et al, “Dipeptidyl Peptidase-IV Inhibitor Use Associated with Increased Risk of ACE Inhibitor-Associated Angioedema,” <i>Hypertension</i>, 2009, 54(3):516-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19581505\">[PubMed 19581505]</a></p>\n<p>2. Prescribing information. Onglyza (saxagliptin). Princeton, NJ: Bristol-Myers Squibb, 07/2009.</p>\n<p>3. Prescribing information. Januvia (sitagliptin). Whitehouse Station, NJ: Merck &amp; Co., Inc., 02/2010.</p>\n<p>4. Byrd JB, Touzin K, Sile S, et al, “Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor Associated Angioedema,” <i>Hypertension</i>, 2008, 51(1):141-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18025295\">[PubMed 18025295]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5387":"<p><b>Title</b> ClomiPRAMINE / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of ClomiPRAMINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased systemic effects of clomipramine with regular coadministration of grapefruit juice, or decreased effects if regular administration of grapefruit juice is discontinued.</p> \n<p><b>Discussion</b> Serum clomipramine concentrations (25 mg 3 times/day) increased approximately threefold in a pediatric patient within 3 days of administering each dose with grapefruit juice (250 mL).<sup>1</sup> Prior to adding the grapefruit juice, the patient was experiencing little benefit from the clomipramine. Subsequent to adding the grapefruit juice he experienced sustained benefit. A second patient in the same report (also a clomipramine nonresponder) experienced an approximate 50% increase in serum clomipramine concentrations within 3 days of coadministration with grapefruit juice. This increase was not associated with a change in clinical condition. <br><br>The likely mechanism of this interaction is inhibition of CYP3A4 mediated clomipramine metabolism by constituents in grapefruit juice.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Oesterheld J and Kallepalli BR, “Grapefruit Juice and Clomipramine: Shifting Metabolic Ratios,” <i>J Clin Psychopharmacol</i>, 1997, 17:62-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9004067\">[PubMed 9004067]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5389":"<p><b>Title</b> Agalsidase Beta / Gentamicin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gentamicin (Systemic) may diminish the therapeutic effect of Agalsidase Beta. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant administration of gentamicin with agalsidase beta as it could theoretically antagonize intracellular alpha-galactosidase activity.</p> \n<p><b>Discussion</b> Canadian prescribing information for agalsidase beta states that coadministration of gentamicin should be avoided due to a possible risk of diminished intracellular alpha-galactosidase activity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product Monograph. Fabrazyme (agalsidase beta). Mississauga, ON: Genzyme Canada Inc., October 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5390":"<p><b>Title</b> Tetrabenazine / Metoclopramide</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Metoclopramide may enhance the adverse/toxic effect of Tetrabenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of metoclopramide in combination with other agents associated with development of extrapyramidal reactions (e.g. tardive dyskinesia) or neuroleptic malignant syndrome.</p> \n<p><b>Discussion</b> The use of metoclopramide in combination with other agents associated with development of neuroleptic malignant syndrome or extrapyramidal reactions such as tardive dyskinesia should be avoided per metoclopramide prescribing information.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D<sub>1</sub> receptors) and striatopallidal pathway (at dopamine D<sub>2</sub> receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D<sub>2</sub> receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. The pathophysiology of neuroleptic malignant syndrome is poorly understood, but the syndrome is associated with many of the same drugs (e.g. antipsychotics, serotonergic antidepressants) as extrapyramidal side effects and similar precautions regarding the use of multiple associated agents should be taken.<sup>1,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Metozolv (metoclopramide HCl). Morrisville, North Carolina: Salix Pharmaceuticals, September 2009.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS and Camilleri M, “Review Article: Metoclopramide and Tardive Dyskinesia,” <i>Aliment Pharmacol Ther</i>, 2010, 31(1):11-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Stevens DL, “Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome,” <i>Ann Pharmacother</i>, 2008, 42(9):1290-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18628446\">[PubMed 18628446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5391":"<p><b>Title</b> Immunosuppressants / Denosumab</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Denosumab may enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for signs/symptoms of serious infections when using denosumab together with an immunosuppressant. Advise patients to immediately report any symptoms of possible infections.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine<br><b>Exception</b> Cytarabine (Liposomal)</p>\n</div> \n<p><b>Discussion</b> According to denosumab prescribing information, the risk of nonfatal serious infections was higher with denosumab than with placebo (4.0% vs. 3.3%) in a study of postmenopausal women with osteoporosis (n=7808).<sup>1</sup> The overall incidence of infections and the incidence of fatal infections were both similar in the denosumab and placebo groups. Based on these data, and knowledge that denosumab may alter lymphocyte function, the prescribing information cautions that patients on immunosuppressant therapy may be at greater risk for infections when using denosumab.<sup>1</sup><br><br>The mechanism of this possible interaction is likely that the denosumab target, the receptor activator of nuclear factor kappa-B ligand (RANKL), is normally expressed on activated T and B lymphocytes, meaning that denosumab-mediated RANKL inhibition may alter normal lymphocyte activity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Prolia (denosumab). Thousand Oaks, CA: Amgen Inc., 06/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5392":"<p><b>Title</b> Cefditoren / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Cefditoren. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Cefditoren prescribing information recommends to avoid concomitant use with antacids and H2-antagonists (eg, famotidine, ranitidine) as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided in patients receiving cefditoren therapy, separation of dosing by several hours <b>may</b> minimize the risk of interaction.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of cefditoren (400 mg single dose) was decreased 11% when coadministered with a single dose of an antacid containing magnesium (800 mg) and aluminum (900 mg) hydroxides.<sup>1</sup> The absorption of the cephalosporin appears to be impaired by the antacid. The clinical significance of this interaction is unknown but appears to be minor. Cefditoren prescribing information however recommends against concomitant use with antacids.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Spectracef (cefditoren). Cary, NC: Cornerstone Therapeutics, 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5393":"<p><b>Title</b> Cefditoren / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Cefditoren. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> The AUC of cefditoren (400 mg single dose) was decreased 22% when coadministered with a single IV dose of the H2-antagonist famotidine (20 mg).<sup>1</sup> Impaired cefditoren absorption, caused by the increased gastric pH might explain this interaction, although the precise mechanism is unknown. The clinical significance of this interaction is unknown as well, however cefditoren prescribing information recommends against concomitant use with H2-antagonists (eg, famotidine, ranitidine). Though not described in the manufacturer labeling, a similar risk of interaction might be anticipated with proton pump inhibitors (PPIs).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Spectracef (cefditoren). Cary, NC: Cornerstone Therapeutics, 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5394":"<p><b>Title</b> NIFEdipine / CYP3A4 Inducers (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Genotype</b>: PXR/NR1|2 haplotype appears to alter the inducibility of nifedipine metabolism.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid coadministration of nifedipine with strong CYP3A4 inducers. Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers. Other dihydropyridine calcium channel blockers will likely interact with CYP3A4 inducers to at least some degree. If using this combination, monitor patients closely for clinical signs of diminished nifedipine response.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> According to data in nifedipine prescribing information, the mean nifedipine AUC and maximum serum concentration (Cmax) were reduced by 97% and 95%, respectively, when nifedipine (20 mg x1) was given after 14 days of pretreatment with rifampin (600 mg/day) in a study of 12 healthy volunteers.<sup>1</sup> These findings are consistent with those of published studies of healthy volunteers that have reported several-fold increases in nifedipine clearance and substantially reduced nifedipine bioavailability when nifedipine was coadministered with rifampin.<sup>2,3</sup> Relatively similar effects on nifedipine concentrations have been observed with other drugs that are inducers of CYP3A, with concurrent phenytoin associated with an approximate 70% decrease in nifedipine AUC and concurrent St John's wort associated with a 29-48% decrease in nifedipine AUC.<sup>1,4,5,6</sup><br><br>At least 2 published case reports highlight the likely clinical significance of this interaction. In one report, a patient with previously controlled hypertension on nifedipine experienced a loss of blood pressure control after starting rifampin.<sup>7</sup> Another patient who was taking nifedipine for control of angina also experienced a loss of nifedipine effectiveness shortly after starting concurrent rifampin.<sup>8</sup><br><br>The mechanism of this interaction appears to be induction of hepatic and intestinal CYP3A4, resulting in reduced nifedipine bioavailability. Data from one study that evaluated both oral and intravenous nifedipine support the key role of intestinal CYP3A4 in this interaction, finding little evidence for a substantial change in the hepatic extraction of nifedipine (but a large increase for gut wall extraction) and only a small impact on the pharmacokinetics of intravenous nifedipine.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Adalat</i> (nifedipine) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2008.</p>\n<p>2. Ndanusa BU, Mustapha A, Abdu-Aguye I. The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. <i>J Pharm Biomed Anal</i>. 1997;15(9-10):1571-1575. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9226591\">[PubMed 9226591]</a></p>\n<p>3. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. <i>Drug Metab Dispos</i>. 1996;24(10):1121-1123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8894514\">[PubMed 8894514]</a></p>\n<p>4. <i>Procardia</i> (nifedipine) [prescribing information]. New York, NY: Pfizer Inc; July 2013.</p>\n<p>5. <i>Procardia XL</i> (nifedipine) [prescribing information]. New York, NY: Pfizer Inc; July 2013.</p>\n<p>6. Wang XD, Li JL, Su QB, et al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. <i>Br J Clin Pharmacol</i>. 2009;67(2):255-261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19173680\">[PubMed 19173680]</a></p>\n<p>7. Tada Y, Tsuda Y, Otsuka T, et al. Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension. <i>Am J Med Sci</i>. 1992;303(1):25-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1345893\">[PubMed 1345893]</a></p>\n<p>8. Tsuchihashi K, Fukami K, Kishimoto H, et al. A case of variant angina exacerbated by administration of rifampicin. <i>Heart Vessels</i>. 1987;3(4):214-217. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3453828\">[PubMed 3453828]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5395":"<p><b>Title</b> Lithium / Topiramate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Topiramate may increase the serum concentration of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased lithium levels/adverse affects with topiramate initiation/dose increase (particularly with higher doses; eg, 600 mg/day). Conversely, monitor for decreased lithium levels with topiramate discontinuation/dose decrease.</p> \n<p><b>Discussion</b> A few case reports describe increased lithium serum concentrations and apparent related toxicities in patients receiving topiramate (75 mg/day)<sup>1</sup> and (800 mg/day).<sup>2</sup> In 31 bipolar patients randomized to receive lithium (dose not specified) and topiramate (up to 200 mg/day [low dose] or up to 600 mg/day [high dose]), lithium AUC and Cmax in the high dose topiramate group remained unchanged after 1 week but increased respectively by approximately 27% after 3 weeks.<sup>3</sup> Low dose topiramate had no effect on lithium pharmacokinetics and similarly, lithium had no effect on topiramate exposure throughout the treatment period. The exact mechanism for this interaction is unknown, however lithium and topiramate are primarily excreted by the kidney and may compete for renal elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Abraham G and Owen J, “Topiramate Can Cause Lithium Toxicity,” <i>J Clin Psychopharmacol</i>, 2004, 24(5):565-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15349023\">[PubMed 15349023]</a></p>\n<p>2. Pinninti N and Zelinski G, “Does Topiramate Elevate Serum Lithium Levels,” <i>J Clin Psychopharmacol</i>, 2002, 22(3):340. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12006910\">[PubMed 12006910]</a></p>\n<p>3. Prescribing information. Topamax (topiramate). Toronto, Ontario: Janssen-Ortho Inc., April 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5396":"<p><b>Title</b> Dienogest / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for signs or symptoms of dienogest adverse effects if dienogest is used together with a strong inhibitor of CYP3A4.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The average dienogest AUC and maximum serum concentration (Cmax) were increased 186% and 94%, respectively, with concurrent ketoconazole, according to data in the estradiol valerate/dienogest prescribing information.<sup>1</sup><br><br>Considering that dienogest is metabolized by CYP3A4 and ketoconazole is a strong CYP3A4 inhibitor, the mechanism of this interaction is thought to be ketoconazole inhibition of dienogest metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Natazia (estradiol valerate and estradiol valerate/dienogest). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 05/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5397":"<p><b>Title</b> Dienogest / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer. An alternative form of contraception should be used during this time.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Dienogest AUC was an average of 83% lower following 5 days of concurrent rifampin (600 mg/d) in a study of 16 healthy, postmenopausal women.<sup>1</sup> The average dienogest maximum serum concentration (Cmax) was reduced by 52%. Considering data such as these, estradiol valerate/dienogest prescribing information recommends avoiding use of this product with CYP3A4 inducers, such as rifampin, as well as for at least 28 days following discontinuation of any such CYP3A4 inducers.<sup>1</sup><br><br>The mechanism of this interaction appears to be increased dienogest CYP3A4-mediated metabolism by enzyme inducers such as rifampin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Natazia (estradiol valerate and estradiol valerate/dienogest). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 05/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5398":"<p><b>Title</b> EpiRUBicin / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of EpiRUBicin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid cimetidine during treatment with epirubicin.</p> \n<p><b>Discussion</b> In a clinical study mentioned in epirubicin prescribing information, administration of cimetidine (400 mg twice daily, starting 5 days before epirubicin) increased AUC of epirubicin (100 mg/m2) by 50% and decreased its clearance by 30%.<sup>1</sup> In a clinical study of 8 patients with breast cancer, coadministration of cimetidine (400 mg orally twice daily, starting 5 days before epirubicin) increased AUC or epirubicin (100 mg/m2) by 50% and increased AUC of the metabolites epirubicinol and 7-deoxy-doxorubicin aglycone by a median of 41% and 357%, respectively.<sup>2</sup><br><br>The mechanism of this interaction is unclear. Prescribing information for epirubicin recommends that cimetidine treatment be stopped during epirubicin treatment.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ellence (epirubicin hydrochloride). Kalamazoo, MI: Pharmacia &amp; Upjohn Company, February 2005.</p>\n<p>2. Murray LS, Jodrell DI, Morrison JG, et al, “The Effect of Cimetidine on the Pharmacokinetics of Epirubicin in Patients with Advanced Breast Cancer: Preliminary Evidence of a Potentially Common Drug Interaction,” <i>Clin Oncol (R Coll Radiol)</i>, 1998, 10(1):35-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9543613\">[PubMed 9543613]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","5399":"<p><b>Title</b> Vitamin K Antagonists / Toremifene</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Toremifene may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Toremifene prescribing information recommends careful monitoring of prothrombin time during concomitant therapy with coumarin-type anticoagulants.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> Prescribing information for toremifene recommends careful monitoring of prothrombin time during concomitant therapy with coumarin-type anticoagulants, citing a known interaction between antiestrogenic compounds of the triphenylethylene derivative class and coumarin-type anticoagulants.<sup>1</sup><br><br>The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Fareston (toremifene citrate). Memphis, TN: GTx, Inc, December 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}